fact_key,concept,context_ref,value,unit_ref,decimals,numeric_value,period_type,period_start,period_end,entity_identifier,entity_scheme,period_key,label,original_label,statement_type,statement_role,dim_srt_RangeAxis,dim_us-gaap_DebtInstrumentAxis,dim_us-gaap_LongtermDebtTypeAxis,period_instant,dim_us-gaap_StatementEquityComponentsAxis,dim_us-gaap_RestructuringCostAndReserveAxis,dim_us-gaap_RestructuringPlanAxis,dim_us-gaap_ConcentrationRiskByTypeAxis,dim_srt_ProductOrServiceAxis,dim_us-gaap_TypeOfArrangementAxis,dim_srt_StatementScenarioAxis,dim_us-gaap_FairValueByMeasurementFrequencyAxis,dim_us-gaap_FinancialInstrumentAxis,dim_us-gaap_FairValueByFairValueHierarchyLevelAxis,dim_us-gaap_FairValueByAssetClassAxis,dim_us-gaap_IncomeStatementLocationAxis,dim_us-gaap_SubsidiarySaleOfStockAxis,dim_us-gaap_StatementClassOfStockAxis,dim_us-gaap_DebtInstrumentRedemptionPeriodAxis,dim_us-gaap_StatementBusinessSegmentsAxis,dim_srt_CounterpartyNameAxis,ticker,filing_date,quarter,year,company_name
dei_EntityCentralIndexKey_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityCentralIndexKey,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0001621227,None,None,1621227.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Central Index Key,Entity Central Index Key,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_CurrentFiscalYearEndDate_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:CurrentFiscalYearEndDate,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,--12-31,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Current Fiscal Year End Date,Current Fiscal Year End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentFiscalYearFocus_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentFiscalYearFocus,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,2025,None,None,2025.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Fiscal Year Focus,Document Fiscal Year Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentFiscalPeriodFocus_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentFiscalPeriodFocus,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,Q1,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Fiscal Period Focus,Document Fiscal Period Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_AmendmentFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:AmendmentFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amendment Flag,Amendment Flag,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityTaxIdentificationNumber_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityTaxIdentificationNumber,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,00-0000000,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Tax Identification Number,Entity Tax Identification Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_cyhWQ53Aa0yj9lG1blzo-g,us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration,Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_cyhWQ53Aa0yj9lG1blzo-g,http://fasb.org/us-gaap/2024#PrimeRateMember,None,None,,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,"Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]","Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,srt:MaximumMember,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rItK1v8OWE2Qjp7rfbhArg,us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration,Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rItK1v8OWE2Qjp7rfbhArg,http://fasb.org/us-gaap/2024#PrimeRateMember,None,None,,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,"Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]","Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,srt:MinimumMember,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]","Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentType_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentType,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,10-Q,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Type,Document Type,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentQuarterlyReport_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentQuarterlyReport,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,true,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Quarterly Report,Document Quarterly Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentPeriodEndDate_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentPeriodEndDate,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,2025-03-31,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Period End Date,Document Period End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_DocumentTransitionReport_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:DocumentTransitionReport,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Document Transition Report,Document Transition Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityFileNumber_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityFileNumber,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,001-37368,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Securities Act File Number,Securities Act File Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityRegistrantName_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityRegistrantName,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ADAPTIMMUNE THERAPEUTICS PLC,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Registrant Name,Entity Registrant Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityIncorporationStateCountryCode_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityIncorporationStateCountryCode,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,X0,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Entity Incorporation, State or Country Code","Entity Incorporation, State or Country Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityAddressAddressLine1_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityAddressAddressLine1,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"60 Jubilee Avenue, Milton Park",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Entity Address, Address Line One","Entity Address, Address Line One",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityAddressCityOrTown_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityAddressCityOrTown,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"Abingdon, Oxfordshire",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Entity Address, City or Town","Entity Address, City or Town",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityAddressPostalZipCode_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityAddressPostalZipCode,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,OX14 4RX,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Entity Address, Postal Zip Code","Entity Address, Postal Zip Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityAddressCountry_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityAddressCountry,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,GB,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Entity Address, Country","Entity Address, Country",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_CityAreaCode_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:CityAreaCode,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,44,None,None,44.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,City Area Code,City Area Code,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_LocalPhoneNumber_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:LocalPhoneNumber,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1235 430000,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Local Phone Number,Local Phone Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_Security12bTitle_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:Security12bTitle,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Title of 12(b) Security,Title of 12(b) Security,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_TradingSymbol_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:TradingSymbol,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ADAP,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Trading Symbol,Trading Symbol,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_SecurityExchangeName_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:SecurityExchangeName,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,NASDAQ,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Security Exchange Name,Security Exchange Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityCurrentReportingStatus_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityCurrentReportingStatus,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,Yes,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Current Reporting Status,Entity Current Reporting Status,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityInteractiveDataCurrent_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityInteractiveDataCurrent,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,Yes,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Interactive Data Current,Entity Interactive Data Current,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityFilerCategory_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityFilerCategory,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,Non-accelerated Filer,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Filer Category,Entity Filer Category,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntitySmallBusiness_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntitySmallBusiness,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,true,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Small Business,Entity Small Business,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityEmergingGrowthCompany_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityEmergingGrowthCompany,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Emerging Growth Company,Entity Emerging Growth Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityShellCompany_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,dei:EntityShellCompany,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Entity Shell Company,Entity Shell Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
dei_EntityCommonStockSharesOutstanding_As_Of_5_9_2025_q2h1dquDikulu2yhD2k6Dg,dei:EntityCommonStockSharesOutstanding,As_Of_5_9_2025_q2h1dquDikulu2yhD2k6Dg,1590309546,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1590309546.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-05-09,"Entity Common Stock, Shares Outstanding","Entity Common Stock, Shares Outstanding",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,2025-05-09,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,91139000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,91139000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,18512000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18512000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Marketable securities - amortized cost,Marketable securities - amortized cost,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLossCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,60451000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,60451000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Marketable securities - amortized cost,Marketable securities - amortized cost,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Marketable securities - Net of allowance for expected credit losses,Marketable securities - Net of allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,60466000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,60466000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4382000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4382000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1454000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1454000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,27294000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27294000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,27790000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27790000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AssetsCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,102998000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,102998000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AssetsCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,188169000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,188169000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1950000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1950000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,2067000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2067000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OtherAssetsNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,377000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,377000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Other non-current assets,Other non-current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OtherAssetsNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,629000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,629000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Other non-current assets,Other non-current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,19080000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,19080000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,17750000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,17750000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,19217000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,19217000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Operating lease right-of-use assets, net of accumulated amortization of $19,080 and $17,750","Operating lease right-of-use assets, net of accumulated amortization of $19,080 and $17,750",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,19909000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,19909000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Operating lease right-of-use assets, net of accumulated amortization of $19,080 and $17,750","Operating lease right-of-use assets, net of accumulated amortization of $19,080 and $17,750",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,70048000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,70048000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,51893000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,51893000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:PropertyPlantAndEquipmentNet,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,29724000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,29724000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Property, plant and equipment, net of accumulated depreciation of $70,048 and $51,893","Property, plant and equipment, net of accumulated depreciation of $70,048 and $51,893",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:PropertyPlantAndEquipmentNet,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,31309000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,31309000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Property, plant and equipment, net of accumulated depreciation of $70,048 and $51,893","Property, plant and equipment, net of accumulated depreciation of $70,048 and $51,893",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5819000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5819000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,5567000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5567000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,3806000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3806000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Intangible assets, net of accumulated amortization of $5,819 and $5,567","Intangible assets, net of accumulated amortization of $5,819 and $5,567",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,3880000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3880000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Intangible assets, net of accumulated amortization of $5,819 and $5,567","Intangible assets, net of accumulated amortization of $5,819 and $5,567",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:Assets,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,158072000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,158072000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:Assets,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,245963000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,245963000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AccountsPayableCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5701000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5701000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AccountsPayableCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,8692000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,8692000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4627000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4627000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,4709000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4709000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,12444000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,12444000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,12296000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,12296000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,51072000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,51072000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:LiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,64527000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,64527000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,18668000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18668000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,19263000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,19263000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DeferredRevenueNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:DeferredRevenueNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,95979000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,95979000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DeferredRevenueNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:DeferredRevenueNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,95815000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,95815000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LongTermDebtNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,25411000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,25411000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Borrowings, non-current","Borrowings, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:LongTermDebtNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,50237000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,50237000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Borrowings, non-current","Borrowings, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OtherLiabilitiesNoncurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4371000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4371000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OtherLiabilitiesNoncurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,4272000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4272000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:Liabilities,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,195501000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,195501000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:Liabilities,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,234114000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,234114000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,0.001,Unit_Divide_GBP_shares_z5eBDIECfkqRSXAIuuD_sQ,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,0.001,Unit_Divide_GBP_shares_z5eBDIECfkqRSXAIuuD_sQ,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CommonStockSharesAuthorized,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,2039252874,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,2039252874.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1547093808,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1547093808.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CommonStockSharesIssued,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1547093808,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1547093808.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CommonStockSharesAuthorized,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,2039252874,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,2039252874.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1535653620,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1535653620.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CommonStockSharesIssued,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1535653620,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1535653620.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CommonStockValue,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,2099000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2099000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock - Ordinary shares par value £0.001, 2,039,252,874 authorized and 1,547,093,808 issued and outstanding (2024: 2,039,252,874 authorized and 1,535,653,620 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 2,039,252,874 authorized and 1,547,093,808 issued and outstanding (2024: 2,039,252,874 authorized and 1,535,653,620 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CommonStockValue,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,2085000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2085000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock - Ordinary shares par value £0.001, 2,039,252,874 authorized and 1,547,093,808 issued and outstanding (2024: 2,039,252,874 authorized and 1,535,653,620 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 2,039,252,874 authorized and 1,547,093,808 issued and outstanding (2024: 2,039,252,874 authorized and 1,535,653,620 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AdditionalPaidInCapital,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1106455000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1106455000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AdditionalPaidInCapital,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1105653000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1105653000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,-4412000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4412000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,-1902000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1902000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,-1093987000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1093987000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,158072000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,158072000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,245963000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,245963000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,28857000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,28857000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,35207000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,35207000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_SellingGeneralAndAdministrativeExpense_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:SellingGeneralAndAdministrativeExpense,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,23282000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,23282000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Selling, general and administrative","Selling, general and administrative",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_SellingGeneralAndAdministrativeExpense_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:SellingGeneralAndAdministrativeExpense,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,19732000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,19732000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Selling, general and administrative","Selling, general and administrative",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47009000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47009000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-47977000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47977000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Loss before income tax expense,Loss before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:EarningsPerShareBasic,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-0.03,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,-0.03,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Basic net loss per share (in dollars per share),Basic net loss per share (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:EarningsPerShareDiluted,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-0.03,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,-0.03,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Diluted net loss per share (in dollars per share),Diluted net loss per share (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:EarningsPerShareBasic,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-0.03,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,-0.03,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Basic net loss per share (in dollars per share),Basic net loss per share (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:EarningsPerShareDiluted,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-0.03,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,-0.03,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Diluted net loss per share (in dollars per share),Diluted net loss per share (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1542159622,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1542159622.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Weighted average shares outstanding, Diluted","Weighted average shares outstanding, Diluted",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1451241661,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1451241661.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Weighted average shares outstanding, Diluted","Weighted average shares outstanding, Diluted",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-28193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-28193000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,6815000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6815000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,25703000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,25703000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-5782000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5782000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-20000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-20000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-5000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-50094000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-50094000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-47475000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47475000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total comprehensive loss for the period,Total comprehensive loss for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8O0vZXaXKEmOlOnVMFaXuA,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8O0vZXaXKEmOlOnVMFaXuA,1535653620,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1535653620.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8O0vZXaXKEmOlOnVMFaXuA,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8O0vZXaXKEmOlOnVMFaXuA,2085000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2085000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0UE3vKPlAEua5yBBiDZ_AA,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0UE3vKPlAEua5yBBiDZ_AA,1105653000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1105653000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7OYzG07D0kylZgfeBLbUFA,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7OYzG07D0kylZgfeBLbUFA,-1093987000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1093987000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_0,us-gaap:StockholdersEquity,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,11849000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11849000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_1,us-gaap:StockholdersEquity,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,11849000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11849000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9lSK7xQoh0GqhKEDRG1oRQ,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9lSK7xQoh0GqhKEDRG1oRQ,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_2,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,-2510000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2510000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Other comprehensive income (loss),Other comprehensive income (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-2510000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2510000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Other comprehensive income (loss),Other comprehensive income (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,7738026,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,7738026.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,9000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,9000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinaryShares_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,adap:StockSoldDuringPeriodOrdinaryShares,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,3702162,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,3702162.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5qASKJcCdE2UyGpuuASoJw,5000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WrgZUnhhSkuZkeYFzJwVcw,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WrgZUnhhSkuZkeYFzJwVcw,117000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,117000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,122000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,122000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WrgZUnhhSkuZkeYFzJwVcw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WrgZUnhhSkuZkeYFzJwVcw,685000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,685000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,685000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,685000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a3qVfsrMME-O2bagjbGkXA,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a3qVfsrMME-O2bagjbGkXA,1547093808,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1547093808.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a3qVfsrMME-O2bagjbGkXA,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a3qVfsrMME-O2bagjbGkXA,2099000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2099000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZluV0kvfbk-WRh9TvkME6A,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZluV0kvfbk-WRh9TvkME6A,1106455000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1106455000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MeOXdh-COkSzRaXVjxlutg,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MeOXdh-COkSzRaXVjxlutg,-1141571000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1141571000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:StockholdersEquity,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,-37429000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-37429000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:StockholdersEquity,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,-37429000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-37429000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n5Y93FXx80uDqELpk0rL6w,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n5Y93FXx80uDqELpk0rL6w,1363008102,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1363008102.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2023-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n5Y93FXx80uDqELpk0rL6w,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_n5Y93FXx80uDqELpk0rL6w,1865000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1865000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZG1VLOYJQESClutQrQ7OuA,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ZG1VLOYJQESClutQrQ7OuA,1064569000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1064569000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9w_pTY-J6Ui2WCvIto5wGQ,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9w_pTY-J6Ui2WCvIto5wGQ,-1023173000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1023173000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_KKg5pcsBNk6fRxopCn3Rtw,us-gaap:StockholdersEquity,As_Of_12_31_2023_KKg5pcsBNk6fRxopCn3Rtw,39513000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,39513000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WsgtsGUFJUyJPFTFH8VbeQ,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WsgtsGUFJUyJPFTFH8VbeQ,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_2,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,1028000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1028000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other comprehensive income (loss),Other comprehensive income (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1028000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1028000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other comprehensive income (loss),Other comprehensive income (loss),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,6297720,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,6297720.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,8000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,8000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,66000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,66000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,74000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,74000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinaryShares_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,adap:StockSoldDuringPeriodOrdinaryShares,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,163669056,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,163669056.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZblaSh-jQkGqomViwfn88g,208000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,208000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,28953000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,28953000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinarySharesValue_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,adap:StockSoldDuringPeriodOrdinarySharesValue,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,29161000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,29161000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses","Issue of shares under At The Market sales agreement, net of commission and expenses",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6TuzF1e8-EOo3A4zC745bQ,3102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3102000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,3102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3102000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tdzhsQ7PB0i9PnCxN1KjLg,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tdzhsQ7PB0i9PnCxN1KjLg,1532974878,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1532974878.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tdzhsQ7PB0i9PnCxN1KjLg,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tdzhsQ7PB0i9PnCxN1KjLg,2081000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2081000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oRz-qF2BUEKAoe4OubJ1_A,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oRz-qF2BUEKAoe4OubJ1_A,1096690000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1096690000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0dsHAt2F0O0qCkLoxuwFQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_V0dsHAt2F0O0qCkLoxuwFQ,-1071676000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1071676000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,24375000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,24375000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProfitLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss,Net loss,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ProfitLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss,Net loss,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ShareBasedCompensation,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,669000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,669000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ShareBasedCompensation,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,3102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3102000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-396000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-396000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Unrealized foreign exchange (gains)/losses,Unrealized foreign exchange (gains)/losses,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,305000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,305000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Unrealized foreign exchange (gains)/losses,Unrealized foreign exchange (gains)/losses,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccretionAmortizationOnAvailableForSaleDebtSecurities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:AccretionAmortizationOnAvailableForSaleDebtSecurities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-431000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-431000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Accretion of available-for-sale debt securities,Accretion of available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccretionAmortizationOnAvailableForSaleDebtSecurities_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,adap:AccretionAmortizationOnAvailableForSaleDebtSecurities,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-23000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-23000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Accretion of available-for-sale debt securities,Accretion of available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,33000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,33000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-19000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-19000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-1582000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1582000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,(Increase)/decrease in receivables and other operating assets,(Increase)/decrease in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,15620000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,15620000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,(Increase)/decrease in receivables and other operating assets,(Increase)/decrease in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInInventories_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncreaseDecreaseInInventories,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-4426000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4426000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Increase in inventories,Increase in inventories,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-13011000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-13011000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Decrease in payables and other current liabilities,Decrease in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-7650000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-7650000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Decrease in payables and other current liabilities,Decrease in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncreaseDecreaseInOtherNoncurrentAssets,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,281000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,281000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Decrease in noncurrent assets,Decrease in noncurrent assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_IncreaseInBorrowingsAndOtherNonCurrentLiabilities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:IncreaseInBorrowingsAndOtherNonCurrentLiabilities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,606000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,606000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Increase in borrowings and other non-current liabilities,Increase in borrowings and other non-current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-3217000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3217000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,(Decrease)/increase in deferred revenue,(Decrease)/increase in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,2388000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2388000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,(Decrease)/increase in deferred revenue,(Decrease)/increase in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-31950000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-31950000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-1203000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1203000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-102000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-256000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-256000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Acquisition of intangible assets,Acquisition of intangible assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,58440000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,58440000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Maturity, redemption or sale of marketable securities","Maturity, redemption or sale of marketable securities",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireMarketableSecurities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:PaymentsToAcquireMarketableSecurities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-16090000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-16090000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Investment in marketable securities,Investment in marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,7000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,41154000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,41154000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net cash provided by/(used in) investing activities,Net cash provided by/(used in) investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-358000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-358000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash provided by/(used in) investing activities,Net cash provided by/(used in) investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RepaymentsOfDebt_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RepaymentsOfDebt,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-25451000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-25451000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Repayment of borrowings,Repayment of borrowings,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,122000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,122000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,29161000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,29161000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,9000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,74000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,74000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-25320000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-25320000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net cash (used in)/provided by financing activities,Net cash (used in)/provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,29235000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,29235000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net cash (used in)/provided by financing activities,Net cash (used in)/provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,556000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,556000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-416000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-416000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-50202000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-50202000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Net decrease in cash, cash equivalents and restricted cash","Net decrease in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-3489000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3489000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Net decrease in cash, cash equivalents and restricted cash","Net decrease in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,93206000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,93206000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2023_KKg5pcsBNk6fRxopCn3Rtw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2023_KKg5pcsBNk6fRxopCn3Rtw,147017000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,147017000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,2023-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,43004000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,43004000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,143528000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,143528000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NatureOfOperations_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NatureOfOperations,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 1 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> General</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom (“U.K”). Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a commercial-stage biopharmaceutical company primarily focused on the treatment of solid tumor cancers with cell therapies. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early commercial and clinical development stages including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. Even though the Company has obtained marketing approval for its first cell therapy, TECELRA® (afamitresgene autoleucel) (“TECELRA”), it will take a period of time before any significant revenue is realized and the amount of revenue is heavily dependent on the success of commercialization and the costs of supplies including any post-marketing requirements the Company is subject to. The Company had an accumulated deficit of $1,141,571,000 as of March 31, 2025.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,General,General,Disclosures,http://www.adaptimmune.com/role/DisclosureGeneral,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,-1141571000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1141571000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,-1141571000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,-1141571000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 2 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Summary of Significant Accounting Policies </b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s 2024 Annual Report. The condensed consolidated balance sheet as of December 31, 2024, as presented herein, was derived from audited consolidated financial statements included in the Company’s 2024 Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)</b>          <b style=""font-weight:bold;"">Going concern</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In accordance with Accounting Standards Codification (“ASC”) 205-40, <i style=""font-style:italic;"">Going Concern</i>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has identified conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The Company’s cash and cash equivalents are primarily used in its operating activities. As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $59.6 million and used $66.6 million cash in operating activities during the three months ended March 31, 2025. The Company expects negative cash flows from operations to continue, for at least the next twelve months, as the ramp up of its commercialization of TECELRA continues.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""white-space:pre-wrap;"">Based on the Company’s current cash and cash equivalents, anticipated cash outflows for operating and financing activities and likely cash inflows from customers, Management does not believe that the Company’s existing cash, cash equivalents and marketable securities will be sufficient to fund its operating activities (including in relation to its obligations arising under the Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities and Hercules Capital, Inc. (“Hercules Capital”) entered into on May 14, 2024) for at least the next 12 months from the filing date of this Quarterly Report. As detailed further in Note 13 and our Annual Report on Form 10-K for the year ended December 31, 2024, the Company is also subject to certain financial covenants under the Loan Agreement, including the maintenance of cash, cash equivalents and marketable securities to certain levels. If the Company’s cash and cash equivalents and marketable securities fall below certain levels specified in the Hercules Capital Loan Agreement, this would result in a breach of the Company’s financial covenants. If the covenants with Hercules Capital are breached, then Hercules Capital may call in some or all of the outstanding principal (together with early repayment charge).  The Company may have insufficient funds to repay the required amounts at the time that the amount becomes due despite having pre-paid </span>$25<span style=""white-space:pre-wrap;""> million of existing loan under the Loan Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company intends to attempt to mitigate the conditions that give rise to substantial doubt over going concern through a combination of different activities. First the Company is taking immediate steps to reduce its operating costs. These steps include the deprioritization of the PRAME and ADP-520 programs and stopping or deferment of all non-essential operating expenses. Such steps will have a short-term impact on operating expenses and also a longer-term impact on the amount of funding required for activities in the medium term. Despite these steps, further sources of funding will still need to be identified and we are actively looking at a variety of strategic opportunities. The Company has engaged TD Securities (USA) LLC (“TD Cowen”) to evaluate strategic options for the Company and all of its programs. These strategic options could include potential mergers with third parties or acquisitions of part or all of the business together with other collaborations or partnerships. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As detailed in Note 16, on November 13, 2024, the Company announced a restructuring program to deprioritize certain programs and reduce headcount, in order to reduce operating costs. Although these measures will reduce the Company’s operating costs in the long term, they will not alleviate the conditions that give rise to the substantial doubt over going concern and the Company must acquire additional funding. Whilst the Company has had a successful record of financing the company through various means since its inception, including raising over $1.4 billion through a combination of equity and business development activities, there is no assurance that the Company will be able to obtain sufficient additional capital to continue funding its operations or, if the Company does, that it will be on terms that are favorable to its shareholders.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">If the Company fails to obtain additional funding, it will be required to do some or all of the following:</p><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">further reduce operations of the business. Any such reduction could significantly delay the timelines under which we can bring new products to the market (including lete-cel) or our ability to commercialize TECELRA;</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">conduct a further restructuring of the company to further reduce headcount and expenditure which will in turn reduce the activities and operations of the business;</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">repay the remaining loan advance received under the Loan Agreement in accordance with the terms of the Loan Agreement (including any applicable repayment charges, end of term charges or other costs);</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">seek an acquirer or alternative party for a merger for all or part of the business or its assets on terms that are less favorable than might otherwise be available; or</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">relinquish or license on unfavorable terms or rights to technologies, intellectual property or product candidates we would otherwise seek to develop or commercialize ourselves.</span></td></tr></table><div style=""margin-top:12pt;""></div><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">If the Company fails to obtain additional funding, or in the event that the Company further significantly reduces its ongoing expenditures and operations (including the current restructuring), this may result in an inability to retain the key individuals required for its ongoing business and may result in a need to delay or halt ongoing programs or change the nature and scope of such programs. As a result, our business financial condition and results of operations could be materially affected. Not all of the potential mitigating actions set out above are within the Company’s direct control and may rely on third parties for implementation. The general macro-economic conditions and market and trading environment are also difficult to predict and could adversely affect our ability to put in place mitigating actions. As a result, there is substantial doubt over the Company’s ability to continue as a going concern within 12 months from the date of filing of this Quarterly Report and is not alleviated as of the date of filing.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The consolidated financial statements do not include any adjustments that might result from the Company not being able to alleviate the substantial doubt over going concern. As such, the consolidated financial statements have been prepared on the basis that assumes the Company will be able to continue as a going concern and will be able to fund its operations and satisfy its liabilities, obligations and commitments as they fall due within the ordinary course of business.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(e</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $41,054,000, marketable securities of $18,509,000 and restricted cash of $1,950,000 as of March 31, 2025. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States (“U.S.”) and the U.K. Government Financial Services Compensation Scheme in the U.K. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company made sales of TECELRA to commercial customers and had two development revenue-generating customers during the three months ended March 31, 2025 which are Galapagos NV (“Galapagos”), and GSK. There were accounts receivable of $4,382,000 as of March 31, 2025 and $1,454,000 as of December 31, 2024. The Company has been transacting with Galapagos since 2024 and GSK since 2014 and has been selling products commercially since November 2024, during which time no credit losses have been recognized. As of March 31, 2025, the allowance for expected credit losses was not significant on the basis that the possibility of credit losses arising on its receivables as of March 31, 2025 is considered to be remote.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyzes current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(f)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improvements to Income Tax Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which improves income tax disclosures primarily relating to the rate reconciliation and income taxes paid information. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company intends to adopt the guidance in its Annual Report on Form 10-K for the fiscal year beginning January 1, 2025. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Disaggregation of Income Statement Expenses</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In November 2024, the FASB issued ASU 2024-03 Disaggregation of Income Statement Expense, which improves disclosure around the nature of expenses included in the income statement. The improvements require entities to disaggregate and disclose the amounts of certain types of expenses included in certain expense captions. For public business entities, the guidance is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company intends to adopt the guidance in its Annual Report on Form 10-K for the fiscal year beginning January 1, 2027. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of Significant Accounting Policies,Summary of Significant Accounting Policies,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_BasisOfAccountingPolicyPolicyTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:BasisOfAccountingPolicyPolicyTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s 2024 Annual Report. The condensed consolidated balance sheet as of December 31, 2024, as presented herein, was derived from audited consolidated financial statements included in the Company’s 2024 Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Basis of presentation,Basis of presentation,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_UseOfEstimates_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:UseOfEstimates,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, the fair value of assets acquired, liabilities assumed, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Use of estimates in interim financial statements,Use of estimates in interim financial statements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_GoingConcernPolicyTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:GoingConcernPolicyTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)</b>          <b style=""font-weight:bold;"">Going concern</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In accordance with Accounting Standards Codification (“ASC”) 205-40, <i style=""font-style:italic;"">Going Concern</i>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has identified conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The Company’s cash and cash equivalents are primarily used in its operating activities. As of March 31, 2025, the Company had cash, cash equivalents and marketable securities of $59.6 million and used $66.6 million cash in operating activities during the three months ended March 31, 2025. The Company expects negative cash flows from operations to continue, for at least the next twelve months, as the ramp up of its commercialization of TECELRA continues.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""white-space:pre-wrap;"">Based on the Company’s current cash and cash equivalents, anticipated cash outflows for operating and financing activities and likely cash inflows from customers, Management does not believe that the Company’s existing cash, cash equivalents and marketable securities will be sufficient to fund its operating activities (including in relation to its obligations arising under the Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities and Hercules Capital, Inc. (“Hercules Capital”) entered into on May 14, 2024) for at least the next 12 months from the filing date of this Quarterly Report. As detailed further in Note 13 and our Annual Report on Form 10-K for the year ended December 31, 2024, the Company is also subject to certain financial covenants under the Loan Agreement, including the maintenance of cash, cash equivalents and marketable securities to certain levels. If the Company’s cash and cash equivalents and marketable securities fall below certain levels specified in the Hercules Capital Loan Agreement, this would result in a breach of the Company’s financial covenants. If the covenants with Hercules Capital are breached, then Hercules Capital may call in some or all of the outstanding principal (together with early repayment charge).  The Company may have insufficient funds to repay the required amounts at the time that the amount becomes due despite having pre-paid </span>$25<span style=""white-space:pre-wrap;""> million of existing loan under the Loan Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company intends to attempt to mitigate the conditions that give rise to substantial doubt over going concern through a combination of different activities. First the Company is taking immediate steps to reduce its operating costs. These steps include the deprioritization of the PRAME and ADP-520 programs and stopping or deferment of all non-essential operating expenses. Such steps will have a short-term impact on operating expenses and also a longer-term impact on the amount of funding required for activities in the medium term. Despite these steps, further sources of funding will still need to be identified and we are actively looking at a variety of strategic opportunities. The Company has engaged TD Securities (USA) LLC (“TD Cowen”) to evaluate strategic options for the Company and all of its programs. These strategic options could include potential mergers with third parties or acquisitions of part or all of the business together with other collaborations or partnerships. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As detailed in Note 16, on November 13, 2024, the Company announced a restructuring program to deprioritize certain programs and reduce headcount, in order to reduce operating costs. Although these measures will reduce the Company’s operating costs in the long term, they will not alleviate the conditions that give rise to the substantial doubt over going concern and the Company must acquire additional funding. Whilst the Company has had a successful record of financing the company through various means since its inception, including raising over $1.4 billion through a combination of equity and business development activities, there is no assurance that the Company will be able to obtain sufficient additional capital to continue funding its operations or, if the Company does, that it will be on terms that are favorable to its shareholders.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">If the Company fails to obtain additional funding, it will be required to do some or all of the following:</p><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">further reduce operations of the business. Any such reduction could significantly delay the timelines under which we can bring new products to the market (including lete-cel) or our ability to commercialize TECELRA;</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">conduct a further restructuring of the company to further reduce headcount and expenditure which will in turn reduce the activities and operations of the business;</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">repay the remaining loan advance received under the Loan Agreement in accordance with the terms of the Loan Agreement (including any applicable repayment charges, end of term charges or other costs);</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">seek an acquirer or alternative party for a merger for all or part of the business or its assets on terms that are less favorable than might otherwise be available; or</span></td></tr></table><table style=""border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;""><tr><td style=""width:56.25pt;""></td><td style=""font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"">●</td><td style=""padding:0pt;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">relinquish or license on unfavorable terms or rights to technologies, intellectual property or product candidates we would otherwise seek to develop or commercialize ourselves.</span></td></tr></table><div style=""margin-top:12pt;""></div><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">If the Company fails to obtain additional funding, or in the event that the Company further significantly reduces its ongoing expenditures and operations (including the current restructuring), this may result in an inability to retain the key individuals required for its ongoing business and may result in a need to delay or halt ongoing programs or change the nature and scope of such programs. As a result, our business financial condition and results of operations could be materially affected. Not all of the potential mitigating actions set out above are within the Company’s direct control and may rely on third parties for implementation. The general macro-economic conditions and market and trading environment are also difficult to predict and could adversely affect our ability to put in place mitigating actions. As a result, there is substantial doubt over the Company’s ability to continue as a going concern within 12 months from the date of filing of this Quarterly Report and is not alleviated as of the date of filing.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The consolidated financial statements do not include any adjustments that might result from the Company not being able to alleviate the substantial doubt over going concern. As such, the consolidated financial statements have been prepared on the basis that assumes the Company will be able to continue as a going concern and will be able to fund its operations and satisfy its liabilities, obligations and commitments as they fall due within the ordinary course of business.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Going concern,Going concern,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_CashCashEquivalentsAndMarketableSecurities_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:CashCashEquivalentsAndMarketableSecurities,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,59600000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,59600000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Amount of cash, cash equivalents and marketable securities","Amount of cash, cash equivalents and marketable securities",Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-66592000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-66592000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-66600000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,-66600000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentRepaymentsPriorToMaturity_Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_5zVSg9SzeUmZtOU36pkYSg,adap:DebtInstrumentRepaymentsPriorToMaturity,Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_5zVSg9SzeUmZtOU36pkYSg,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,25000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Prepaid amount of existing loan,Prepaid amount of existing loan,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_BusinessDevelopment_Duration_11_13_2024_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember_us-gaap_RestructuringPlanAxis_adap_RestructuringPlanDateMember_dNGYKhtUFUKQQAFIGKAPew,us-gaap:BusinessDevelopment,Duration_11_13_2024_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember_us-gaap_RestructuringPlanAxis_adap_RestructuringPlanDateMember_dNGYKhtUFUKQQAFIGKAPew,1400000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-8,1400000000.0,duration,2024-11-13,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-11-13_2025-03-31,Amount of equity and business development activities,Amount of equity and business development activities,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,None,None,None,None,us-gaap:OtherRestructuringMember,adap:RestructuringPlanDateMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_FairValueMeasurementPolicyPolicyTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:FairValueMeasurementPolicyPolicyTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ConcentrationRiskCreditRisk_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ConcentrationRiskCreditRisk,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(e</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $41,054,000, marketable securities of $18,509,000 and restricted cash of $1,950,000 as of March 31, 2025. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States (“U.S.”) and the U.K. Government Financial Services Compensation Scheme in the U.K. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company made sales of TECELRA to commercial customers and had two development revenue-generating customers during the three months ended March 31, 2025 which are Galapagos NV (“Galapagos”), and GSK. There were accounts receivable of $4,382,000 as of March 31, 2025 and $1,454,000 as of December 31, 2024. The Company has been transacting with Galapagos since 2024 and GSK since 2014 and has been selling products commercially since November 2024, during which time no credit losses have been recognized. As of March 31, 2025, the allowance for expected credit losses was not significant on the basis that the possibility of credit losses arising on its receivables as of March 31, 2025 is considered to be remote.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyzes current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Significant concentrations of credit risk,Significant concentrations of credit risk,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,41054000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,41054000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,41054000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,41054000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,18509000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18509000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,18509000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,18509000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCash_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RestrictedCash,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1950000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,1950000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restricted cash,Restricted cash,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfDevelopmentRevenueGeneratingCustomers_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:NumberOfDevelopmentRevenueGeneratingCustomers,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,2,Unit_Standard_customer_phxLreydVUWKFIhCDt6zTA,INF,2.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Number of development revenue-generating customers,Number of development revenue-generating customers,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2025_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sIkwM-jr5USje5MdIrQsew,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2025_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sIkwM-jr5USje5MdIrQsew,4382000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,4382000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fuP3mQrLO0OScV5AdtbxBg,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2024_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fuP3mQrLO0OScV5AdtbxBg,1454000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,1454000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AssetImpairmentCharges_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:AssetImpairmentCharges,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Impairment losses,Impairment losses,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(f)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Improvements to Income Tax Disclosures</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In December 2023, the FASB issued ASU 2023-09 – Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which improves income tax disclosures primarily relating to the rate reconciliation and income taxes paid information. This includes a tabular reconciliation using both percentages and reporting currency amounts, covering various tax and reconciling items, and disaggregated summaries of income taxes paid during the period. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company intends to adopt the guidance in its Annual Report on Form 10-K for the fiscal year beginning January 1, 2025. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">To be adopted in future periods</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Disaggregation of Income Statement Expenses</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">In November 2024, the FASB issued ASU 2024-03 Disaggregation of Income Statement Expense, which improves disclosure around the nature of expenses included in the income statement. The improvements require entities to disaggregate and disclose the amounts of certain types of expenses included in certain expense captions. For public business entities, the guidance is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company intends to adopt the guidance in its Annual Report on Form 10-K for the fiscal year beginning January 1, 2027. The Company is currently evaluating the impact of the guidance on its Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,New accounting pronouncements,New accounting pronouncements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RevenueFromContractWithCustomerTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 3 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Revenue</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company generates product revenue from sales of TECELRA.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company generates development revenue from collaboration agreements with customers. The Company had two development revenue-generating contracts with customers in the three months ended March 31, 2025 and 2024, respectively: a termination and transfer agreement with GSK that was entered into on April 6, 2023 (the “Termination and Transfer Agreement”), a collaboration and license agreement with Galapagos executed on May 30, 2024 (the “Galapagos Collaboration Agreement”). The collaboration agreement with Genentech was terminated in April 2024 and the termination became effective on September 23, 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:43.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Product revenue, net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,048</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,237</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,285</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,678</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Deferred revenue increased by $312,000 from $108,111,000 at December 31, 2024 to $108,423,000 at March 31, 2025 due to revenue recognized during the period of $3,217,000 that was included in deferred revenue at December 31, 2024 and a $3,547,000 </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">increase caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.25 at December 31, 2024 to £1.00 to $1.30 at March 31, 2025. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of March 31, 2025 was $121,973,000. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-style:italic;font-weight:bold;"">3.1. Product Revenue</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company received U.S. Food and Drug Administration (“FDA”) approval on August 1, 2024, for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy. There are 20 Authorized Treatment Centers (“ATCs”) available to initiate the treatment journey for the patients and ten patients have been apheresed. Product revenue represents sales of TECELRA which is derived from four ATCs during the three months ended March 31, 2025.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-style:italic;font-weight:bold;"">3.2. Development revenue</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Galapagos Collaboration and Exclusive License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""></span>On May 30, 2024, the Company entered into the Galapagos Collaboration Agreement, a clinical collaboration agreement with Galapagos. The Galapagos Collaboration Agreement includes an option for Galapagos to exclusively license the TCR T-cell therapy candidate uza-celuzatresgene autoleucel (“uza-cel”), manufactured on Galapagos’ decentralized manufacturing platform, in head and neck cancer and potential future solid tumor indications. Under the Galapagos Collaboration Agreement, we will conduct a clinical proof-of-concept trial (the “POC Trial”) to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform in patients with head and neck cancer. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Under the terms of the Galapagos Collaboration Agreement, the Company will receive initial payments of $100 million, comprising $70 million upfront and $30 million of research and development funding of which $15 million is due upfront and $15 million is due once the first patient is infused in the POC Trial. In addition, there are option exercise fees of up to $100 million (the amount depending on the number of indications in relation to which the option is exercised), additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales. The $70 million upfront payment and $15 million of upfront research and development funding was received by the Company in June 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company determined that Galapagos is a customer and has accounted for the Galapagos Collaboration Agreement under ASC 606 <i style=""font-style:italic;"">Revenue from Contracts with Customers</i>. The Company has identified a performance obligation relating to the various activities required to complete the POC trial and a material right associated with the exclusive license option.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate transaction price at inception of the Galapagos Collaboration Agreement was $100,000,000 comprising the $70,000,000 upfront payment and the $30,000,000 research and development funding. The fees for the exclusive license option exercise and development milestone payments are not considered probable as of March 31, 2025 and have not been included in the transaction price. The sales milestones and royalties for future sales of therapies have not been included within the transaction price as of March 31, 2025 because they are sales-based and would be recognized when the subsequent sales occur.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the POC Trial. The residual approach was used to value the material right associated with the exclusive license option as the Company has not previously sold uza-cel on a standalone basis and has not established a price for uza-cel.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company expects to satisfy the POC Trial obligation over time over the period that the trial is completed, based on an estimate of the percentage of completion of the trial determined based on the costs incurred on the trial as a percentage of the total expected costs. The revenue allocated to the material right associated with the exclusive licence option will be recognized from the point that the option is either exercised and control of the license has passed to Galapagos or the option lapses.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of March 31, 2025 was $98,965,000, of which $43,365,000 is allocated to the POC Trial performance obligation and $55,600,000 is allocated to the material right for the exclusive option.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Genentech Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On April 12, 2024 the Company announced the termination of the collaboration agreement entered into by Adaptimmune Limited, a wholly-owned subsidiary of the Company, with Genentech on September 3, 2021 (the “Genentech Collaboration Agreement”), in relation to the research, development and commercialization of cancer targeted allogeneic T-cell therapies which was originally scheduled to be effective from October 7, 2024. The termination was accounted for as a contract modification on a cumulative catch-up basis. The termination did not change the nature of the performance obligations identified but resulted in a reduction in the transaction price as the additional payments and variable consideration that would have been due in periods after October 7, 2024 will now never be received.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company originally expected to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progressed and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expected to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options would have been exercised and then as development progressed, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expired. The Company expected to satisfy the performance obligations relating to the material rights to extend the research term from the point that the options would have been exercised and then over the period of the extension, or at the point in time that the rights expired.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate remaining transaction price that had not yet been recognized as revenue as of the date of the termination was $146,301,000 which included the remaining deferred revenue that had not been recognized as revenue as of the date of the modification and the variable consideration to be billed under the collaboration until the effective date of the termination that is still considered probable. The termination resulted in a cumulative catch-up adjustment to revenue at the date of the termination of $101,348,000 and a further $20,741,000 of revenue recognized in the second quarter of 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On September 23, 2024, the Adaptimmune Limited entered into a Mutual Release and Resolution Agreement (the “Mutual Release Agreement”) with Genentech. The Mutual Release Agreement, among other things, resolved and released each party from any and all past, present and future disputes, claims, demands and causes of action, whether known or unknown, related to the Genentech Collaboration Agreement in any way. Under the terms of the Mutual Release Agreement, Genentech will pay the Company $12.5 million upon which the Genentech Collaboration Agreement will be terminated. The Agreement was effective immediately as of September 23, 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Mutual Release Agreement resulted in all remaining performance obligations being fully satisfied and the remaining deferred revenue of $25,298,000 and the additional payment of $12,500,000 were both recognized as total revenue of $37,798,000 in the third quarter of 2024.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The GSK Termination and Transfer Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On April 6, 2023, the Company and GSK entered into the Termination and Transfer Agreement, regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As part of the Termination and Transfer Agreement, sponsorship and responsibility for the ongoing IGNYTE and long-term follow-up (“LTFU”) trials relating to the NY-ESO cell therapy program will transfer to the Company. In return for this, the Company received an upfront payment of £7.5 million in June 2023, following the signing of the agreement, and milestone payments of £3 million, £12 million, £6 million and £1.5 million in September and December 2023 and June and August 2024, respectively. No further payments are due from GSK under the Termination and Transfer Agreement.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company determined that GSK is a customer and has accounted for the Termination and Transfer Agreement under ASC 606 <i style=""font-style:italic;"">Revenue from Contracts with Customers</i>. The Termination and Transfer Agreement is accounted for as a separate contract from the </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">original Collaboration and License Agreement with GSK. The Termination and Transfer Agreement was terminated in October 2022 and the termination became effective on December 23, 2022. The Company has identified the following performance obligations under the Termination and Transfer Agreement: (i) to take over sponsorship for the IGNYTE trial and (ii) to take over sponsorship for the LTFU trial.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate transaction price at inception of the agreement was $37,335,000 comprising the total £30,000,000 upfront and milestone payments. No value was ascribed to non-cash consideration and there was no variable consideration identified. The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the relative standalone selling price, the Company considered the internal pricing objectives it used in negotiating the contract, together with internal data regarding the expected costs and a standard margin on those costs, for completing the trials. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company expects to satisfy the performance obligations over time from the point that sponsorship of the active trials that make up the trial transfers and then over the period that the trial is completed, based on the number of patients transferred and still actively enrolled to date on the trial at a given period-end relative to the total estimated periods of active patient enrollment over the estimated duration of the trial. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company considers that this depicts the progress of the completion of the trials under the Termination and Transfer Agreement, as the status of patients on the trial is not directly affected by decisions that the Company might make relating to its own development of the NY-ESO cell therapy program.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of March 31, 2025 was $23,007,000, of which $7,778,000 is allocated to the IGNYTE performance obligation and $15,229,000 is allocated to the LTFU performance obligation.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenue,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:NumberOfContractsWithCustomer,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,2,Unit_Standard_customer_phxLreydVUWKFIhCDt6zTA,INF,2.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DisaggregationOfRevenueTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:DisaggregationOfRevenueTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:43.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Product revenue, net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,048</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,237</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td></tr><tr><td style=""vertical-align:bottom;width:53.15%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,285</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,678</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of revenue categories,Summary of revenue categories,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_09drKb_Lq0mu8CGW-u_JGA_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_09drKb_Lq0mu8CGW-u_JGA,4048000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4048000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,us-gaap:ProductMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_09drKb_Lq0mu8CGW-u_JGA_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_09drKb_Lq0mu8CGW-u_JGA,4048000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4048000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,us-gaap:ProductMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_PO7pmu_Mv0mP4dUq90l-vg_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_PO7pmu_Mv0mP4dUq90l-vg,3237000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3237000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_PO7pmu_Mv0mP4dUq90l-vg_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_PO7pmu_Mv0mP4dUq90l-vg,3237000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3237000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Qvi9mUhRRkaXZfdQPJJmpA_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Qvi9mUhRRkaXZfdQPJJmpA,5678000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5678000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Qvi9mUhRRkaXZfdQPJJmpA_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_Qvi9mUhRRkaXZfdQPJJmpA,5678000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5678000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,7285000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7285000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,7285000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7285000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,5678000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5678000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,5678000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5678000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total revenue,Total revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_IncreaseInContractWithCustomerLiability_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:IncreaseInContractWithCustomerLiability,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,312000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,312000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Deferred revenue increase,Deferred revenue increase,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,108111000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,108111000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:ContractWithCustomerLiability,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,108423000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,108423000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityRevenueRecognized_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,us-gaap:ContractWithCustomerLiabilityRevenueRecognized,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,3217000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,3217000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Revenue recognized in the period,Revenue recognized in the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,3547000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3547000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amount of increase in deferred income caused by the change in the exchange rate,Amount of increase in deferred income caused by the change in the exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1.25,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,2,1.25,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1.3,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,2,1.3,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,121973000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,121973000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfAuthorizedTreatmentCenters_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:NumberOfAuthorizedTreatmentCenters,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,20,Unit_Standard_item_5M3wy-5mQECMOuCBDMz-fw,INF,20.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Number of Authorized Treatment Centers,Number of Authorized Treatment Centers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfPatientsApheresed_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:NumberOfPatientsApheresed,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,10,Unit_Standard_item_5M3wy-5mQECMOuCBDMz-fw,INF,10.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Number of patients apheresed,Number of patients apheresed,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfAuthorizedTreatmentCenters_As_Of_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_HpA2O4lYDE-42kqaOtqS0Q,adap:NumberOfAuthorizedTreatmentCenters,As_Of_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_HpA2O4lYDE-42kqaOtqS0Q,4,Unit_Standard_item_5M3wy-5mQECMOuCBDMz-fw,INF,4.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Number of Authorized Treatment Centers,Number of Authorized Treatment Centers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,us-gaap:ProductMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TransactionPrice_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_QZbNIrUzVE-Xv5CtP5FJIQ,adap:TransactionPrice,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_QZbNIrUzVE-Xv5CtP5FJIQ,100000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,100000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amount of transaction price of the agreement at inception,Amount of transaction price of the agreement at inception,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_2c_Ql1b3u0eRx60NSVaZ7Q,adap:UpfrontPaymentReceived,Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_2c_Ql1b3u0eRx60NSVaZ7Q,70000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,70000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,adap:LicenseAgreementMilestonePayments,Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,30000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,30000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:ResearchAndDevelopmentMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_PotentialPaymentForAchievementOfSpecifiedMilestones_Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,adap:PotentialPaymentForAchievementOfSpecifiedMilestones,Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,15000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,15000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Potential milestone payments to be received,Potential milestone payments to be received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:ResearchAndDevelopmentMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,adap:UpfrontPaymentReceived,Duration_1_1_2025_To_3_31_2025_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_SrPE1v66WkyaDwMRktnfnw,15000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,15000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:ResearchAndDevelopmentMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_OptionExerciseFee_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_aw95ippTJUmj9jjJ4bJ8DQ,adap:OptionExerciseFee,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_aw95ippTJUmj9jjJ4bJ8DQ,100000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,100000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amount of option exercise fees,Amount of option exercise fees,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_FutureMilestonePayments_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_adap_DevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_P2xld3nmjkWpMjgEvfRi-A,adap:FutureMilestonePayments,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_adap_DevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_P2xld3nmjkWpMjgEvfRi-A,465000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,465000000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Potential amount of additional milestone payment,Potential amount of additional milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:DevelopmentMilestoneMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_6_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_eI3l2AppyE-E1mfctMs2Rw,adap:UpfrontPaymentReceived,Duration_6_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_eI3l2AppyE-E1mfctMs2Rw,70000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,70000000.0,duration,2024-06-01,2024-06-30,0001621227,http://www.sec.gov/CIK,duration_2024-06-01_2024-06-30,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_6_1_2024_To_6_30_2024_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_w2OopEAEE0qt2VXfSoZpFA,adap:LicenseAgreementMilestonePayments,Duration_6_1_2024_To_6_30_2024_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_w2OopEAEE0qt2VXfSoZpFA,15000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,15000000.0,duration,2024-06-01,2024-06-30,0001621227,http://www.sec.gov/CIK,duration_2024-06-01_2024-06-30,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:ResearchAndDevelopmentMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TransactionPrice_As_Of_5_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_nzbSqJN5sE2SarcaJ50YtA,adap:TransactionPrice,As_Of_5_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_nzbSqJN5sE2SarcaJ50YtA,100000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,100000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-30,Amount of transaction price of the agreement at inception,Amount of transaction price of the agreement at inception,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,2024-05-30,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_5_30_2024_To_5_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_-Bvd8rtMnEeLq4lWT8lzaQ,adap:UpfrontPaymentReceived,Duration_5_30_2024_To_5_30_2024_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_-Bvd8rtMnEeLq4lWT8lzaQ,70000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,70000000.0,duration,2024-05-30,2024-05-30,0001621227,http://www.sec.gov/CIK,duration_2024-05-30_2024-05-30,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_5_30_2024_To_5_30_2024_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_HKi440-s-U2oE0_JzwmZWQ,adap:LicenseAgreementMilestonePayments,Duration_5_30_2024_To_5_30_2024_srt_StatementScenarioAxis_adap_ResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_HKi440-s-U2oE0_JzwmZWQ,30000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,30000000.0,duration,2024-05-30,2024-05-30,0001621227,http://www.sec.gov/CIK,duration_2024-05-30_2024-05-30,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,adap:ResearchAndDevelopmentMember,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_QZbNIrUzVE-Xv5CtP5FJIQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_QZbNIrUzVE-Xv5CtP5FJIQ,98965000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,98965000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_srt_ProductOrServiceAxis_adap_PoofOfConceptTrialMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_4Sk3a6HlVU-fbPBq6Qm3AA,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_srt_ProductOrServiceAxis_adap_PoofOfConceptTrialMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_4Sk3a6HlVU-fbPBq6Qm3AA,43365000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,43365000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,adap:PoofOfConceptTrialMember,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_srt_ProductOrServiceAxis_adap_MaterialRightForExclusiveOptionMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_H3PSBoKQDUeN13qNMrQsXg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_srt_ProductOrServiceAxis_adap_MaterialRightForExclusiveOptionMember_us-gaap_TypeOfArrangementAxis_adap_GalapagosCollaborationAndExclusiveLicenseAgreementMember_H3PSBoKQDUeN13qNMrQsXg,55600000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,55600000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,adap:MaterialRightForExclusiveOptionMember,adap:GalapagosCollaborationAndExclusiveLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TransactionPriceContractModification_As_Of_4_12_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_WMcKYJXeakeDEb8hAUF6hQ,adap:TransactionPriceContractModification,As_Of_4_12_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_WMcKYJXeakeDEb8hAUF6hQ,146301000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,146301000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-04-12,Aggregate remaining transaction price that had not yet been recognized as revenue,Aggregate remaining transaction price that had not yet been recognized as revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,2024-04-12,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_Duration_4_12_2024_To_4_12_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember__GYH7VOMdUKWn8SnPc6uRA,us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract,Duration_4_12_2024_To_4_12_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember__GYH7VOMdUKWn8SnPc6uRA,101348000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,101348000.0,duration,2024-04-12,2024-04-12,0001621227,http://www.sec.gov/CIK,duration_2024-04-12_2024-04-12,Amount of cumulative catch-up adjustment at the date of the termination,Amount of cumulative catch-up adjustment at the date of the termination,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityRevenueRecognized_Duration_4_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_OqgosiNnZUCttDHfa9y2DA,us-gaap:ContractWithCustomerLiabilityRevenueRecognized,Duration_4_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_OqgosiNnZUCttDHfa9y2DA,20741000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,20741000.0,duration,2024-04-01,2024-06-30,0001621227,http://www.sec.gov/CIK,duration_2024-04-01_2024-06-30,Revenue recognized in the period,Revenue recognized in the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_PaymentsOfMilestone_As_Of_9_23_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_cL194tRI20y8oYW5FMLKNw,adap:PaymentsOfMilestone,As_Of_9_23_2024_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_cL194tRI20y8oYW5FMLKNw,12500000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,12500000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-09-23,Payments of milestone,Payments of milestone,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,2024-09-23,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DeferredIncomeRevenueRecognizedDueToContractEnding_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_Vf8P3pUZ5E-hS3SbCpMPTg,adap:DeferredIncomeRevenueRecognizedDueToContractEnding,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_Vf8P3pUZ5E-hS3SbCpMPTg,25298000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,25298000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amount of deferred income that was subsequently recognized as revenue due to the contract ending,Amount of deferred income that was subsequently recognized as revenue due to the contract ending,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_PaymentsOfAdditionalMilestone_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_Vf8P3pUZ5E-hS3SbCpMPTg,adap:PaymentsOfAdditionalMilestone,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_Vf8P3pUZ5E-hS3SbCpMPTg,12500000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,12500000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Payments of additional milestone,Payments of additional milestone,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_RevenueRecognizedOnTerminationOfContract_Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_JkKomTjBuUWt9SXHSQhd2A,adap:RevenueRecognizedOnTerminationOfContract,Duration_1_1_2025_To_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_JkKomTjBuUWt9SXHSQhd2A,37798000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,37798000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total revenue recognized on termination of the contract,Total revenue recognized on termination of the contract,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontPaymentReceived_Duration_6_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_kJnZjizBxESB5cm7CQteDA,adap:UpfrontPaymentReceived,Duration_6_1_2023_To_6_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_kJnZjizBxESB5cm7CQteDA,7500000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-5,7500000.0,duration,2023-06-01,2023-06-30,0001621227,http://www.sec.gov/CIK,duration_2023-06-01_2023-06-30,Upfront payment received,Upfront payment received,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_9_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_9lAG8YQ550OkU96lk664fw,adap:MilestonePayments,Duration_9_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_9lAG8YQ550OkU96lk664fw,3000000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-6,3000000.0,duration,2023-09-01,2023-09-30,0001621227,http://www.sec.gov/CIK,duration_2023-09-01_2023-09-30,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_12_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_0iZWTygiCESLpajCKWRhew,adap:MilestonePayments,Duration_12_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_0iZWTygiCESLpajCKWRhew,12000000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-6,12000000.0,duration,2023-12-01,2023-12-31,0001621227,http://www.sec.gov/CIK,duration_2023-12-01_2023-12-31,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_VetL5LSlPkieC4pr2nDwFQ,adap:MilestonePayments,Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_VetL5LSlPkieC4pr2nDwFQ,12000000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-6,12000000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_6_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_l0i4rMPvsUWMZzNU4LRkxg,adap:MilestonePayments,Duration_6_1_2024_To_6_30_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_l0i4rMPvsUWMZzNU4LRkxg,6000000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-6,6000000.0,duration,2024-06-01,2024-06-30,0001621227,http://www.sec.gov/CIK,duration_2024-06-01_2024-06-30,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_8_1_2024_To_8_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_JTs5ykoj50ecDWIsdz8_eA,adap:MilestonePayments,Duration_8_1_2024_To_8_31_2024_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_JTs5ykoj50ecDWIsdz8_eA,1500000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,-5,1500000.0,duration,2024-08-01,2024-08-31,0001621227,http://www.sec.gov/CIK,duration_2024-08-01_2024-08-31,Milestone payment,Milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,None,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TransactionPrice_As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_nCvv_FrXxkielJl0hgG7Tw,adap:TransactionPrice,As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_nCvv_FrXxkielJl0hgG7Tw,37335000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,37335000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-04-06,Amount of transaction price of the agreement at inception,Amount of transaction price of the agreement at inception,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueGalapagosCollaborationDetails,None,None,None,2023-04-06,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_UpfrontAndMilestonePaymentReceivable_As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_nCvv_FrXxkielJl0hgG7Tw,adap:UpfrontAndMilestonePaymentReceivable,As_Of_4_6_2023_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_nCvv_FrXxkielJl0hgG7Tw,30000000,Unit_Standard_GBP_UFb26AmV3ku0aYeMUXCMQA,0,30000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-04-06,Upfront and milestone payment receivable,Upfront and milestone payment receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskTerminationAndTransferAgreementDetails,None,None,None,2023-04-06,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_g8FJ9EKWh0S6WN3Azbn9Uw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_GskTerminationAndTransferAgreementMember_g8FJ9EKWh0S6WN3Azbn9Uw,23007000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,23007000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:GskTerminationAndTransferAgreementMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_IgnyteMember_apAs05h4MUC_iMxJ4ToKew,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_IgnyteMember_apAs05h4MUC_iMxJ4ToKew,7778000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,7778000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:IgnyteMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_LtfuMember_Xlh6b8wHrkmNXIDDifzjjg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2025_us-gaap_TypeOfArrangementAxis_adap_LtfuMember_Xlh6b8wHrkmNXIDDifzjjg,15229000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,15229000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate amount of the transaction price that is allocated to performance obligations,Aggregate amount of the transaction price that is allocated to performance obligations,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,2025-03-31,None,None,None,None,None,adap:LtfuMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:EarningsPerShareTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 4 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Loss per share</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (47,584)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (48,503)</p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (47,584)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic and diluted loss per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,542,159,622</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,451,241,661</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The dilutive effect of 277,952,929 and 249,957,127 stock options outstanding for the three months ended March 31, 2025 and 2024 respectively, have been excluded from the diluted loss per share calculation because they would have an antidilutive effect on the loss per share for the period.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Loss per share,Loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShare,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net loss attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (47,584)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (48,503)</p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net loss attributable to ordinary shareholders used for basic and diluted loss per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (47,584)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:25.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic and diluted loss per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,542,159,622</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,451,241,661</p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of numerator and denominator in the basic and diluted loss per share computation,Schedule of numerator and denominator in the basic and diluted loss per share computation,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_3,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_3,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders used for diluted loss per share,Net loss attributable to ordinary shareholders used for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders used for basic loss per share,Net loss attributable to ordinary shareholders used for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders used for diluted loss per share,Net loss attributable to ordinary shareholders used for diluted loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders used for basic loss per share,Net loss attributable to ordinary shareholders used for basic loss per share,Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1542159622,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1542159622.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1542159622,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1542159622.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1451241661,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1451241661.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1451241661,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,1451241661.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Weighted average number of shares used to calculate basic loss per share,Weighted average number of shares used to calculate basic loss per share,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,277952929,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,277952929.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Employee stock options (in shares),Employee stock options (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,249957127,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,0,249957127.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Employee stock options (in shares),Employee stock options (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureLossPerShareBasicAndDilutedLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNoteTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ComprehensiveIncomeNoteTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 5 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accumulated other comprehensive (loss)/income</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(losses) gains on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,919)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 17</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,902)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (28,193)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (28,193)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,703</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,703</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (20)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (20)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (4,409)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (4,412)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,754)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,748)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,721)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,720)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Accumulated other comprehensive (loss)/income,Accumulated other comprehensive (loss)/income,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossIncome,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(losses) gains on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,919)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 17</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,902)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (28,193)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (28,193)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,703</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,703</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (20)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (20)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (4,409)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (4,412)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,754)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,748)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,815</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,782)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,721)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (2,720)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of changes in accumulated other comprehensive (loss) income,Schedule of changes in accumulated other comprehensive (loss) income,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossIncomeTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_qKPQQQh89UO6F0cEcEMqGg,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_qKPQQQh89UO6F0cEcEMqGg,-1919000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1919000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1cmIIHzcgEC7M9D3a1S0mg,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1cmIIHzcgEC7M9D3a1S0mg,17000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,17000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5RbhxDnC6UK313IktdIuwQ_0,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5RbhxDnC6UK313IktdIuwQ,-1902000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1902000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5RbhxDnC6UK313IktdIuwQ_1,us-gaap:StockholdersEquity,As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5RbhxDnC6UK313IktdIuwQ,-1902000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1902000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_47MUBgOz3ki8quGzRx4qZw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_47MUBgOz3ki8quGzRx4qZw,-28193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-28193000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,-28193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-28193000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_47MUBgOz3ki8quGzRx4qZw,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_47MUBgOz3ki8quGzRx4qZw,25703000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,25703000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,25703000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,25703000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_GfF21eRrB0qhdxuYgUTNIw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_GfF21eRrB0qhdxuYgUTNIw,-20000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-20000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_TkRTaQ-kTU6m1WfrTBKh-A,-20000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-20000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_VykrpcUEa022k0fT28cqww,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_VykrpcUEa022k0fT28cqww,-4409000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4409000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Pfkgxqjqu0ylcds6jmHFzw,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_Pfkgxqjqu0ylcds6jmHFzw,-3000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uQpDafD67EuluFJTaZwAsQ_0,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uQpDafD67EuluFJTaZwAsQ,-4412000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4412000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uQpDafD67EuluFJTaZwAsQ_1,us-gaap:StockholdersEquity,As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uQpDafD67EuluFJTaZwAsQ,-4412000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4412000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_v3E7pd5UHEqEbhnVMDtDvw,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_v3E7pd5UHEqEbhnVMDtDvw,-3754000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3754000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_IN0iTQjgbUmyGgLWcFXNxg,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_IN0iTQjgbUmyGgLWcFXNxg,6000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ygjkP5Jl0-FPVF1pFk1vQ_0,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ygjkP5Jl0-FPVF1pFk1vQ,-3748000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3748000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ygjkP5Jl0-FPVF1pFk1vQ_1,us-gaap:StockholdersEquity,As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ygjkP5Jl0-FPVF1pFk1vQ,-3748000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3748000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2023-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nLFaiCv1EECk6-jjDLJT-g,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nLFaiCv1EECk6-jjDLJT-g,6815000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6815000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,6815000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6815000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nLFaiCv1EECk6-jjDLJT-g,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_nLFaiCv1EECk6-jjDLJT-g,-5782000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5782000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,-5782000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5782000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains/(losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding losses on available-for-sale debt securities, tax","Unrealized holding losses on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6z86Nw21JEaFLcxkEWlcyA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6z86Nw21JEaFLcxkEWlcyA,-5000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cVivywKStkWD4wuAkYMlZQ,-5000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-5000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding losses on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c-3nGsMEA0KzYdxU6wFjUA,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_c-3nGsMEA0KzYdxU6wFjUA,-2721000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2721000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_QfQM89q9s0ujiOJ4OS6ZOQ,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_QfQM89q9s0ujiOJ4OS6ZOQ,1000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ryfPrpCbk26gdJcCrAuKA_0,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ryfPrpCbk26gdJcCrAuKA,-2720000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2720000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ryfPrpCbk26gdJcCrAuKA_1,us-gaap:StockholdersEquity,As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ryfPrpCbk26gdJcCrAuKA,-2720000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2720000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_FairValueDisclosuresTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:FairValueDisclosuresTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 6 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2025 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,205</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 6,988</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,509</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 6,580</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 11,929</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurements,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2025 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,205</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 6,988</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,509</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 6,580</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 11,929</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_hO4-J0wEx0KessABWv_V4w,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_hO4-J0wEx0KessABWv_V4w,6988000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_R1Cc0BYxTEOhO-c-rvdMKg,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_R1Cc0BYxTEOhO-c-rvdMKg,6988000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_73cswy-swEqd_ak0Xvh1nw,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_73cswy-swEqd_ak0Xvh1nw,2205000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_v0cB9Ys0y0SLu0mArZQv7A,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_v0cB9Ys0y0SLu0mArZQv7A,2205000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehH_KYnzV0eJyXjiD5cn_A,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehH_KYnzV0eJyXjiD5cn_A,9193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9193000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U_C_FePTw0OMcHZjQgMpww,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U_C_FePTw0OMcHZjQgMpww,2205000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_juztV7EW_UGgzM9vfgXIjA,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_juztV7EW_UGgzM9vfgXIjA,6988000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Cash equivalents,Cash equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_73cswy-swEqd_ak0Xvh1nw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_73cswy-swEqd_ak0Xvh1nw,6580000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6580000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_v0cB9Ys0y0SLu0mArZQv7A,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_v0cB9Ys0y0SLu0mArZQv7A,6580000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6580000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_hO4-J0wEx0KessABWv_V4w,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_hO4-J0wEx0KessABWv_V4w,11929000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_R1Cc0BYxTEOhO-c-rvdMKg,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_R1Cc0BYxTEOhO-c-rvdMKg,11929000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehH_KYnzV0eJyXjiD5cn_A,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehH_KYnzV0eJyXjiD5cn_A,18509000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18509000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U_C_FePTw0OMcHZjQgMpww,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_U_C_FePTw0OMcHZjQgMpww,6580000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6580000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_juztV7EW_UGgzM9vfgXIjA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_juztV7EW_UGgzM9vfgXIjA,11929000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0","Marketable securities - available-for-sale debt securities (amortized cost of $18,512 and $60,451) net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 7 — Marketable securities – available-for-sale debt securities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2025, the Company had the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.968956%;padding-left:0pt;padding-right:0pt;width:101.93%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,582</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,930</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,512</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,509</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2025 and December 31, 2024 are as follows:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2025 and December 31, 2024 are as follows: </p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,263</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,679</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 18,918</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 26,181</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,679</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2025, no allowance for expected credit losses has been recognized in relation to the securities in an unrealized loss position. This is because the unrealized losses are not severe and do not represent a significant proportion of the total fair market value of the investments and the security has an investment-grade credit rating.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">During the three months ended March 31, 2025, the Company sold investments in marketable securities with a principal of $4,940,000 (based on the specific identification method) for proceeds of $4,940,000.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2025, the Company had the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.968956%;padding-left:0pt;padding-right:0pt;width:101.93%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,988</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,205</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 9,193</b></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,582</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,580</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,930</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,929</p></td></tr><tr><td style=""vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,512</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (3)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 18,509</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of marketable securities,Schedule of marketable securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_NW0rCcCKyU-PyvjBXEcj7w,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_NW0rCcCKyU-PyvjBXEcj7w,P3M,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Available for sale securities debt maturity period,Available for sale securities debt maturity period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_cK8sJF1kLUW2JpLIjaxZjQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_cK8sJF1kLUW2JpLIjaxZjQ,6988000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_cK8sJF1kLUW2JpLIjaxZjQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_cK8sJF1kLUW2JpLIjaxZjQ,6988000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_UF55LdyLUkub7v66R8Ug9g,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_UF55LdyLUkub7v66R8Ug9g,P3M,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Available for sale securities debt maturity period,Available for sale securities debt maturity period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_kWYpL758ck633TMSS1MPYQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_kWYpL758ck633TMSS1MPYQ,2205000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_kWYpL758ck633TMSS1MPYQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_kWYpL758ck633TMSS1MPYQ,2205000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,us-gaap:CashAndCashEquivalentsMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,9193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9193000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,9193000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,9193000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_rKMUdRn_KkSIeYT-AsdIVA,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_rKMUdRn_KkSIeYT-AsdIVA,P3M,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Available for sale securities debt maturity period,Available for sale securities debt maturity period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,6582000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6582000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,2000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_YrltPNBGgkSDp30PYmZsQQ,6580000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6580000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_SiA3mIXWLU2yRK5OvxBDGQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2025_To_3_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_SiA3mIXWLU2yRK5OvxBDGQ,P3M,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Available for sale securities debt maturity period,Available for sale securities debt maturity period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,11930000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11930000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,1000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_UsTreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember_VV8szFfxJ0CxwKxiu4I2lA,11929000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,adap:U.s.TreasurySecuritiesMaturityPeriodLessThanThreeMonthsMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,18512000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18512000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,3000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,18509000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18509000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,7263000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7263000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,-3,Unit_Standard_security_1AzXN0ijHEKVQuYpK7PAbQ,INF,-3.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_kOJq5l4wQUWRsEenBM2cTA,2000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,4679000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4679000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,-2,Unit_Standard_security_1AzXN0ijHEKVQuYpK7PAbQ,INF,-2.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_dQHbsiFIqUuC3xq-y-pYDA,3000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,18918000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,18918000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,-6,Unit_Standard_security_1AzXN0ijHEKVQuYpK7PAbQ,INF,-6.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_HE3nrvLRfke5W9UJTrM1iQ,1000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,us-gaap:USTreasuryBillSecuritiesMember,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,26181000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,26181000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Fair market value of investments in an unrealized loss position,Fair market value of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,-9,Unit_Standard_security_1AzXN0ijHEKVQuYpK7PAbQ,INF,-9.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Number of available-for-sale securities in an unrealized loss position,Number of available-for-sale securities in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss,As_Of_3_31_2025_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_r_WcBnPazEqmqxMJwyzfvQ,3000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,4679000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4679000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Fair market value of investments in an unrealized loss position,Fair market value of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,-2,Unit_Standard_security_1AzXN0ijHEKVQuYpK7PAbQ,INF,-2.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Number of available-for-sale securities in an unrealized loss position,Number of available-for-sale securities in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss,As_Of_12_31_2024_us-gaap_FairValueByAssetClassAxis_adap_MarketableSecuritiesMember_q6Gobx6wFE2j4orB4FnAQg,3000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,adap:MarketableSecuritiesMember,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Marketable securities - Net of allowance for expected credit losses,Marketable securities - Net of allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Marketable securities - Net of allowance for expected credit losses,Marketable securities - Net of allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtSecuritiesAvailableForSalePrincipalSold_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:DebtSecuritiesAvailableForSalePrincipalSold,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,4940000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,4940000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Principal of sold investments,Principal of sold investments,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,4940000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,4940000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Proceeds from sale,Proceeds from sale,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherCurrentAssetsTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OtherCurrentAssetsTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 8 — Other current assets</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 14,693</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,929</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,475</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 10,033</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,777</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,599</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,349</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,170</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,294</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,790</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Research and development credits receivable as of March 31, 2025 primarily relate to the claim for the year ended December 31, 2024.<span style=""background:#ffff00;""> </span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 14,693</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 12,929</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,475</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 10,033</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,777</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,599</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,349</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,170</p></td></tr><tr><td style=""vertical-align:bottom;width:73.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,294</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,790</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of other current assets,Summary of other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:TaxCreditReceivableCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,14693000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,14693000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,adap:TaxCreditReceivableCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,12929000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,12929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:PrepaidExpenseCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,7475000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7475000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:PrepaidExpenseCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,10033000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,10033000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,adap:ClinicalMaterialsCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,59000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,59000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,1777000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1777000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,1599000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1599000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OtherAssetsCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,3349000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3349000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OtherAssetsCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,3170000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3170000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,27294000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27294000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAccountsReceivable,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,27790000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27790000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeasesTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:LesseeOperatingLeasesTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 9 — Operating leases</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has operating leases in relation to property for office, manufacturing and research facilities<span style=""font-size:12pt;"">.</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the lease costs for the three months ended March 31, 2025 and 2024 and the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2025 and 2024:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">The following table shows the lease costs for the three months ended March 31, 2025 and 2024 and the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2025 and 2024:</p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Lease cost:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,627</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,682</p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Short-term lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,638</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,741</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.1 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5.3 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">10.4%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">8.0%</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2025 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,227</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,633</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,263</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,315</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,367</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,753</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 30,558</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,263)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,295</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maximum lease term without activation of termination options is to 2041. </p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Operating leases,Operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeases,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LeaseCostTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:LeaseCostTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">The following table shows the lease costs for the three months ended March 31, 2025 and 2024 and the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2025 and 2024:</p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Lease cost:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Operating lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,627</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,682</p></td></tr><tr><td style=""vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Short-term lease cost</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 59</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,638</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,741</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:20.32%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.1 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">5.3 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">10.4%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">8.0%</span></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of lease cost,Schedule of lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseCost_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:OperatingLeaseCost,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1627000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1627000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Operating lease cost,Operating lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseCost_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:OperatingLeaseCost,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1682000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1682000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Operating lease cost,Operating lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShortTermLeaseCost_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ShortTermLeaseCost,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,11000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Short-term lease cost,Short-term lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShortTermLeaseCost_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:ShortTermLeaseCost,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,59000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,59000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Short-term lease cost,Short-term lease cost,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LeaseCost_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:LeaseCost,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1638000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1638000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LeaseCost_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:LeaseCost,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1741000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1741000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,P6Y1M6D,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,P5Y3M18D,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,0.104,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,3,0.104,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2024_Vfdvtu8kN0SLFDHgZxBTyQ,0.08,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,3,0.08,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,2024-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2025 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,227</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,633</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,263</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,315</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,367</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,753</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 30,558</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,263)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 23,295</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of maturities of operating lease liabilities,Schedule of maturities of operating lease liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5227000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5227000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2025,2025,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4633000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4633000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2026,2026,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4263000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4263000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2027,2027,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4315000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4315000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2028,2028,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4367000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4367000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2029,2029,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,7753000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7753000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,after 2029,after 2029,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,30558000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,30558000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total lease payments,Total lease payments,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,7263000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7263000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Less: Imputed interest,Less: Imputed interest,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiability_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OperatingLeaseLiability,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,23295000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,23295000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Present value of lease liability,Present value of lease liability,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 10 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accrued expenses and other current liabilities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:15.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,344</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,931</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued commercial expenses and provisions</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 532</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 218</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,461</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,529</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,878</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,221</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,648</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,020</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 24,863</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 32,919</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.96%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:15.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:normal;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,344</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,931</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued commercial expenses and provisions</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 532</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 218</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,461</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 13,529</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,878</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,221</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,648</p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,020</p></td></tr><tr><td style=""vertical-align:bottom;width:65.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:12.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 24,863</b></p></td><td style=""vertical-align:bottom;white-space:normal;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:normal;width:4.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:normal;width:11.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 32,919</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of accrued expenses and other current liabilities,Schedule of accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,11344000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11344000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,11931000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11931000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccruedCommercialExpensesAndProvisions_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:AccruedCommercialExpensesAndProvisions,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,532000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,532000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accrued commercial expenses and provisions,Accrued commercial expenses and provisions,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_AccruedCommercialExpensesAndProvisions_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,adap:AccruedCommercialExpensesAndProvisions,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,218000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,218000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accrued commercial expenses and provisions,Accrued commercial expenses and provisions,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5461000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5461000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,13529000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,13529000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,4878000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4878000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,5221000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5221000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:OtherLiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,2648000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2648000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:OtherLiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,2020000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2020000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,24863000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,24863000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,24863000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,24863000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,32919000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,32919000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,32919000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,32919000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 11 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Share-based compensation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (132)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 813</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Selling, general and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 801</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,289</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,102</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">24,711,600</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">37,097,688</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.07</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.12</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">24,944,376</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">26,984,352</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.10</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.14</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Share-based compensation,Share-based compensation,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (132)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 813</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Selling, general and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 801</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,289</p></td></tr><tr><td style=""vertical-align:bottom;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 669</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,102</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of share-based compensation expense included in the consolidated statements of operations,Summary of share-based compensation expense included in the consolidated statements of operations,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4ylChCzAoEG1QAKjsFtYUw,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4ylChCzAoEG1QAKjsFtYUw,-132000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-132000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KrU2LsfpTkKyBp7At9w0Ag,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KrU2LsfpTkKyBp7At9w0Ag,813000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,813000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_diEq-i5_XU6-9kfiziJo3A,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_diEq-i5_XU6-9kfiziJo3A,801000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,801000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6lsuUHc_P0mRELjhtSE0BA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6lsuUHc_P0mRELjhtSE0BA,2289000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2289000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,669000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,669000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,3102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3102000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">24,711,600</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">37,097,688</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.07</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.12</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">24,944,376</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">26,984,352</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.37%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.10</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.14</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of all stock option activity,Summary of all stock option activity,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,24711600,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,24711600.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,37097688,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,37097688.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0.07,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,0.07,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,0.12,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,0.12,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,24944376,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,24944376.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,26984352,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,26984352.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0.1,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,0.1,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,0.14,Unit_Divide_USD_shares_CNO39qhS20mmBiCAthcDFA,2,0.14,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquityNoteDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:StockholdersEquityNoteDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 12 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Stockholders’ equity</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On April 8, 2022 the Company entered into a sales agreement with TD Cowen (the “Sales Agreement”), as amended pursuant to amendment no. 1 to Sales Agreement dated April 18, 2025 (together the “Agreement”), under which we may from time to time issue and sell American Depositary Shares (ADSs) representing our ordinary shares through TD Cowen in “at-the-market” offerings (“ATM”) for an aggregate offering price of up to $200 million. In the three months ended March 31, 2025 the Company sold 1,327,027 ADSs under the Agreement representing 7,962,162 ordinary shares (including 710,000 ADSs sold on March 31, 2025 representing 4,260,000 ordinary shares issued on April 1, 2025) resulting in net proceeds to the Company of $259,477 after deducting commissions payable under the Agreement and issuance costs. As of March 31, 2025, approximately $155,952,137<span style=""white-space:pre-wrap;""> remained available for sale under the Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Stockholders' equity,Stockholders' equity,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_TDmYl9Y0HkOlJBeIMc8wxw,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_TDmYl9Y0HkOlJBeIMc8wxw,200000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,200000000.0,duration,2022-04-08,2022-04-08,0001621227,http://www.sec.gov/CIK,duration_2022-04-08_2022-04-08,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,srt:MaximumMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_pR-NAH0LH06MuIV8urFb4g,adap:StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_pR-NAH0LH06MuIV8urFb4g,1327027,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,1327027.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Sold shares represented by American Depositary Shares (in shares),Sold shares represented by American Depositary Shares (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,dei:AdrMember,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodOrdinaryShares_Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,adap:StockSoldDuringPeriodOrdinaryShares,Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,7962162,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,7962162.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)","Issue of shares under At The Market sales agreement, net of commission and expenses (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues_Duration_3_31_2025_To_3_31_2025_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_uhX2JvWMu0yimXS9Y5ZKPg,adap:StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues,Duration_3_31_2025_To_3_31_2025_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_uhX2JvWMu0yimXS9Y5ZKPg,710000,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,710000.0,duration,2025-03-31,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-03-31_2025-03-31,Sold shares represented by American Depositary Shares (in shares),Sold shares represented by American Depositary Shares (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,dei:AdrMember,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodOrdinaryShares_Duration_4_1_2025_To_4_1_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fbojhMZ2eEe8UznEY2gMxQ,adap:StockIssuedDuringPeriodOrdinaryShares,Duration_4_1_2025_To_4_1_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_fbojhMZ2eEe8UznEY2gMxQ,4260000,Unit_Standard_shares_iz3fBWd2bkaSUODHTOWa0A,INF,4260000.0,duration,2025-04-01,2025-04-01,0001621227,http://www.sec.gov/CIK,duration_2025-04-01_2025-04-01,Number of ordinary shares issued (in shares),Number of ordinary shares issued (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOrSaleOfEquity_Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,us-gaap:ProceedsFromIssuanceOrSaleOfEquity,Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,259477000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,259477000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net proceeds,Net proceeds,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_rRxoy4pOxUKHUY_a3zTxeg,155952137000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,155952137000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Remaining amount under the Sales Agreement,Remaining amount under the Sales Agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:DebtDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 13 – Borrowings</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On May 14, 2024 (the “Closing Date”), we entered the “Loan Agreement for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), and three further term loan advances available to the Company subject to certain terms and conditions in aggregate principal amounts of $25.0 million, $5.0 million and $30.0 million, respectively, and a term loan advance available in the sole discretion of the lenders and subject to certain terms and conditions in the aggregate principal amount of $40.0 million. The proceeds of the Term Loan will be used solely to repay related fees and expenses in connection with the Loan Agreement and for working capital and general corporate purposes.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Term Loan attracts interest on the outstanding principal in the form of both cash and payment-in-kind (“PIK”) interest. The cash interest rate is the <span style=""-sec-ix-hidden:Hidden_fT2AFMRIRk-SF89VMzhsbA;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">greater</span></span> of the <span style=""-sec-ix-hidden:Hidden_Pe4co8UvLU2ujCa9uiT_wQ;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"">Prime Rate</span></span> plus 1.15% and 9.65% and is paid monthly in arrears. The PIK interest rate is 2% per annum. The outstanding principal used to determine both the cash and PIK interest is inclusive of capitalized PIK interest. The Term Loan also attracts an End of Term Charge of 5.85% payable on maturity which is based on the aggregate original principal amount (i.e. excluding capitalized PIK interest).</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Term Loan matures on June 1, 2029 and payments are interest-only until the June 1, 2027 (the “Amortization Date”) after which the monthly payments include repayments of both principal and interest. The Amortization Date can be extended if certain criteria are met and the Company chooses to extend the date. The final Term Loan Maturity Date cannot be extended.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Term Loan is secured by a lien on substantially all of Borrower’s existing or after-acquired assets, including intellectual property, subject to customary exceptions. In addition, the Loan Agreement contains customary closing and commitment fees, prepayment fees and provisions, events of default and representations, warranties and affirmative and negative covenants, including a financial covenant requiring the Company to maintain certain levels of cash in accounts subject to a control agreement in favor of Hercules Capital (the “Qualified Cash”) during the period commencing on January 1, 2025 (which initial commencement date is subject to adjustment if certain performance milestones are met) and at all times thereafter, provided that if the Company has achieved certain performance milestones, the amount of Qualified Cash is subject to certain reductions. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants following any applicable cure period, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the Loan Agreement, cross acceleration to third-party indebtedness and certain events relating to bankruptcy or insolvency.<br/><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Each loan tranche has been identified as a separate unit of account within the scope of ASC 835-30 <i style=""font-style:italic;"">Imputation of interest</i>, with the Tranche 1 Advance constituting a debt instrument and the remaining tranches being loan commitments.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On May 14, 2024, the Company drew down the Tranche 1 Advance of $25,000,000 and received proceeds of $24,500,000 after charges payable to Hercules Capital. The Tranche 1 Advance was initially recognized at $24,750,000. On August 13, 2024, the Company drew down the Tranche 2 Advance of $25,000,000 (the “Tranche 2 Advance,” and, together with the Tranche 1 Advance, the “Tranches” and each a “Tranche”) and received proceeds of $25,000,000. The Tranche 2 Advance was initially recognized at $24,750,000. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On March 24, 2025, Company entered into an amendment to the Loan Agreement to pre-pay $25.0 million of the loan amount with the accrued interest up to the date of such pre-payment. The Company will pay an end of term charge on such pre-paid amount of 5.85% as previously provided in the Loan Agreement, such end of term charge being payable upon maturity or repayment of all obligations under the Loan Agreement. The Company made a $25.4 million pre-payment on March 26, 2025. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The pre-payment was treated as a modification of the Term Loan. The terms of the modified Term Loan are not substantially different to the terms of the original Term Loan, therefore the Term Loan continued to be recognized and a new effective interest rate was calculated based on the carrying amount of the original Term Loan immediately before the modification and the revised future cash flows. As a result of the pre-payment, a loss of $220,000 was recognized relating to the portion of the unamortized discount that was deemed to have been disposed of.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">At March 31, 2025 the face value of the outstanding principal (including capitalized PIK interest) on the Term Loan was $25,323,000, less unamortized discount of $226,000 and plus accreted value of the End of Term Charge of $315,000 based on the imputed interest rate of 14.8%. No qualifying debt issuance costs were incurred in relation to either Tranche.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">At March 31, 2025, the fair value of the Term Loan was $26,070,000. The fair value of the Term Loan is a Level 2 measurement based on observable inputs including the contractual term of the instrument and market interest rates, notably the Prime Rate.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The aggregate maturity of the term loan for the next five years from March 31, 2025 is as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Maturity</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,388</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,808</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,872</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,068</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Composition of principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Original principal</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,000</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Capitalized PIK interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,068</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,068</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The payments included in the table include capitalized PIK interest, as this forms part of the principal balance to be repaid once incurred. Payments relating to cash interest and the End of Term Charge are excluded as they do not constitute repayments of the principal.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Borrowings,Borrowings,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowings,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,125000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,125000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_wKO9CXCoh0STxsBrJkzxDA,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_wKO9CXCoh0STxsBrJkzxDA,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,25000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NumberOfTermLoansAdvancesAvailable_Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_4ijh1h4s5kWUaZX-Sp3wxg,adap:NumberOfTermLoansAdvancesAvailable,Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_4ijh1h4s5kWUaZX-Sp3wxg,3,Unit_Standard_loan_EFnvoP3KUkyLCKhhS1WbfA,INF,3.0,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,Number of term loan advances available,Number of term loan advances available,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qp3tREsHGUKzFyUBkuA6bg,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qp3tREsHGUKzFyUBkuA6bg,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,25000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodTwoMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_tWKOkicX-0SSHXgSJwqGrQ,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_tWKOkicX-0SSHXgSJwqGrQ,5000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,5000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodThreeMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_k8xllquLPESTK-umBitH1Q,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFourMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_k8xllquLPESTK-umBitH1Q,30000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,30000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodFourMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_QObbUZ9Dz0iRclFOfumFlA,us-gaap:DebtInstrumentFaceAmount,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_QObbUZ9Dz0iRclFOfumFlA,40000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,40000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodFiveMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rItK1v8OWE2Qjp7rfbhArg,us-gaap:DebtInstrumentBasisSpreadOnVariableRate1,Duration_5_14_2024_To_5_14_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rItK1v8OWE2Qjp7rfbhArg,0.0115,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,4,0.0115,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,Variable interest rate (in percent),Variable interest rate (in percent),Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,srt:MinimumMember,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtPercentageBearingFixedInterestRate_As_Of_5_14_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_oGwi3D0rxEOyHHHDJQ0oTw,us-gaap:LongTermDebtPercentageBearingFixedInterestRate,As_Of_5_14_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_oGwi3D0rxEOyHHHDJQ0oTw,0.0965,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,4,0.0965,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Fixed interest rate (in percentage),Fixed interest rate (in percentage),Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,srt:MaximumMember,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentPaymentInKindInterestPercentage_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,adap:DebtInstrumentPaymentInKindInterestPercentage,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,0.02,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,2,0.02,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,PIK interest rate (in percent),PIK interest rate (in percent),Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentEndOfTermChargePercentage_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,adap:DebtInstrumentEndOfTermChargePercentage,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember__w3cPPA7hEaJ22NeyIMI0g,0.0585,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,4,0.0585,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,End of term charge (in percent),End of term charge (in percent),Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentAmountDrewDown_Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,adap:DebtInstrumentAmountDrewDown,Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,25000000.0,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,Amount drew down,Amount drew down,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfLongTermDebt_Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,us-gaap:ProceedsFromIssuanceOfLongTermDebt,Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,24500000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,24500000.0,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,Proceeds from issuance of debt,Proceeds from issuance of debt,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentInitialAmountRecognized_As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_wKO9CXCoh0STxsBrJkzxDA,adap:DebtInstrumentInitialAmountRecognized,As_Of_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_wKO9CXCoh0STxsBrJkzxDA,24750000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,24750000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-05-14,Initial amount recognized,Initial amount recognized,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-05-14,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentFaceAmount_As_Of_8_13_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_r4m1gEBrmku3GhOMd4Ih4A,us-gaap:DebtInstrumentFaceAmount,As_Of_8_13_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_r4m1gEBrmku3GhOMd4Ih4A,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,25000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-08-13,Amount of term loan facility,Amount of term loan facility,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-08-13,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodTwoMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfLongTermDebt_Duration_8_13_2024_To_8_13_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Ugkgax83q0m8aevDsyDiWg,us-gaap:ProceedsFromIssuanceOfLongTermDebt,Duration_8_13_2024_To_8_13_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Ugkgax83q0m8aevDsyDiWg,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,25000000.0,duration,2024-08-13,2024-08-13,0001621227,http://www.sec.gov/CIK,duration_2024-08-13_2024-08-13,Proceeds from issuance of debt,Proceeds from issuance of debt,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,srt:MaximumMember,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodTwoMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentInitialAmountRecognized_As_Of_8_13_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_r4m1gEBrmku3GhOMd4Ih4A,adap:DebtInstrumentInitialAmountRecognized,As_Of_8_13_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_r4m1gEBrmku3GhOMd4Ih4A,24750000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,24750000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-08-13,Initial amount recognized,Initial amount recognized,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2024-08-13,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodTwoMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentPrePayAmount_As_Of_3_24_2025_GzTtZEgKH0uTJ4nOmKXQbg,adap:DebtInstrumentPrePayAmount,As_Of_3_24_2025_GzTtZEgKH0uTJ4nOmKXQbg,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,25000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-24,Pre-pay amount,Pre-pay amount,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,None,None,2025-03-24,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentEndOfTermChargePercentage_As_Of_3_24_2025_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_DURUqYKoBECwCOcVgHlDeg,adap:DebtInstrumentEndOfTermChargePercentage,As_Of_3_24_2025_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_DURUqYKoBECwCOcVgHlDeg,0.0585,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,4,0.0585,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-24,End of term charge (in percent),End of term charge (in percent),Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,None,us-gaap:NotesPayableToBanksMember,2025-03-24,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentPrePayAmount_As_Of_3_26_2025_ZctP7fC_CkWeTxXTl_ZPtQ,adap:DebtInstrumentPrePayAmount,As_Of_3_26_2025_ZctP7fC_CkWeTxXTl_ZPtQ,25400000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-5,25400000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-26,Pre-pay amount,Pre-pay amount,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,None,None,2025-03-26,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_GainsLossesOnExtinguishmentOfDebt_Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_5zVSg9SzeUmZtOU36pkYSg,us-gaap:GainsLossesOnExtinguishmentOfDebt,Duration_1_1_2025_To_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_5zVSg9SzeUmZtOU36pkYSg,220000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,220000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Unamortized discount loss,Unamortized discount loss,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentCarryingAmount_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qk0RW6qMDUibWN8SPlBGhQ,us-gaap:DebtInstrumentCarryingAmount,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qk0RW6qMDUibWN8SPlBGhQ,25323000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,25323000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Outstanding borrowings,Outstanding borrowings,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentUnamortizedDiscount_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,us-gaap:DebtInstrumentUnamortizedDiscount,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,226000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,226000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Amount of unamortized discount,Amount of unamortized discount,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtInstrumentAccretedEndOfTermCharge_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,adap:DebtInstrumentAccretedEndOfTermCharge,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,315000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,315000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Accreted value of the End of Term Charge,Accreted value of the End of Term Charge,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentInterestRateEffectivePercentage_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qk0RW6qMDUibWN8SPlBGhQ,us-gaap:DebtInstrumentInterestRateEffectivePercentage,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_Qk0RW6qMDUibWN8SPlBGhQ,0.148,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,3,0.148,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Imputed interest rate,Imputed interest rate,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_DebtIssuanceCostsIncurred_Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,adap:DebtIssuanceCostsIncurred,Duration_5_14_2024_To_5_14_2024_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_SLYhriUfMECmt8BpPJv-KQ,0,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,0.0,duration,2024-05-14,2024-05-14,0001621227,http://www.sec.gov/CIK,duration_2024-05-14_2024-05-14,Debt issuance costs incurred,Debt issuance costs incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtInstrumentRedemptionPeriodOneMember,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtFairValue_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rwJmiPgYPEGgLu3H7UagBg,us-gaap:LongTermDebtFairValue,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_rwJmiPgYPEGgLu3H7UagBg,26070000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,26070000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Fair value of term loan,Fair value of term loan,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The aggregate maturity of the term loan for the next five years from March 31, 2025 is as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Maturity</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,388</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2028</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,808</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2029</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,872</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,068</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Composition of principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Original principal</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,000</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Capitalized PIK interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,068</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total principal repayments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 27,068</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of aggregate maturity of the term loan,Schedule of aggregate maturity of the term loan,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,6388000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,6388000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2027,2027,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,11808000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11808000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2028,2028,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,8872000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,8872000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,2029,2029,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_DebtInstrumentCarryingAmount_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,us-gaap:DebtInstrumentCarryingAmount,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,25000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,25000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Outstanding borrowings,Outstanding borrowings,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsNarrativeDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_LongTermDebtCapitalizedPaymentInKindInterest_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,adap:LongTermDebtCapitalizedPaymentInKindInterest,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,2068000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2068000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Capitalized PIK interest,Capitalized PIK interest,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebt_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ_0,us-gaap:LongTermDebt,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,27068000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27068000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total principal repayments,Total principal repayments,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LongTermDebt_As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ_1,us-gaap:LongTermDebt,As_Of_3_31_2025_us-gaap_DebtInstrumentAxis_adap_LoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_ZpeF7WjS9EC8VF9F_1nULQ,27068000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,27068000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total principal repayments,Total principal repayments,Disclosures,http://www.adaptimmune.com/role/DisclosureBorrowingsMaturityDetails,None,adap:LoanAndSecurityAgreementMember,us-gaap:NotesPayableToBanksMember,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_SegmentReportingDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:SegmentReportingDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 14 – Segment reporting</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company has one reportable segment relating to the research, development and commercialization of its novel cell therapies. The segment derives its current revenues from research and development collaborations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer and the senior leadership team (comprising the Executive Team members and three senior vice presidents), manages the Company’s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company’s financial performance, the CODM regularly reviews total revenues, total expenses and expenses by function and the CODM makes decisions using this information on a global basis.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:30.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:30.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,285</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Cost of goods sold</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (879)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Research</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,108)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,800)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">CMC and Quality</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,085)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,200)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Biomarkers</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,222)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,500)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Development and Compliance</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,550)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Infrastructure management and Facilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,339)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,700)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Commercial and Commercial planning</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,398)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Support and corporate functions</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,639)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,000)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Other segment expenses<sup style=""font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,798)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,539)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total operating expenses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (53,018)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (54,939)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Operating loss</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (45,733)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (49,261)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest income</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 910</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,345</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,881)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other income (expense), net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (305)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Income tax expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (575)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (526)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Segment and consolidated net loss</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (47,584)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup>Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits of $1,238,000 (2024: $3,499,000), depreciation of $2,291,000 (2024: $2,771,000), amortization of $175,000 (2024: $59,000) and share-based compensation expenses (see Note 11), respectively.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Segment reporting,Segment reporting,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReporting,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NumberOfReportableSegments_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:NumberOfReportableSegments,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1,Unit_Standard_segment_3z8gRbv06E-dlV4dOjyvLw,INF,1.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Number of reportable segments,Number of reportable segments,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:30.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:30.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,285</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,678</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Cost of goods sold</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (879)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Research</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,108)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,800)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">CMC and Quality</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,085)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (14,200)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Biomarkers</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,222)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,500)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Development and Compliance</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (10,550)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Infrastructure management and Facilities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,339)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (7,700)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Commercial and Commercial planning</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,398)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,600)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Support and corporate functions</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (12,639)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (9,000)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Other segment expenses<sup style=""font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,798)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,539)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total operating expenses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (53,018)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (54,939)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Operating loss</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (45,733)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (49,261)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest income</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 910</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,345</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Interest expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,881)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other income (expense), net</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (305)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (61)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Income tax expense</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (575)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (526)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Segment and consolidated net loss</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (47,584)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (48,503)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">(a)</sup>Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits of $1,238,000 (2024: $3,499,000), depreciation of $2,291,000 (2024: $2,771,000), amortization of $175,000 (2024: $59,000) and share-based compensation expenses (see Note 11), respectively.</p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Summary of the segment profit or loss,Summary of the segment profit or loss,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Revenues_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:Revenues,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,7285000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7285000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingSegmentProfitOrLossDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Revenues_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,us-gaap:Revenues,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,5678000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5678000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingSegmentProfitOrLossDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostOfGoodsAndServicesSold_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:CostOfGoodsAndServicesSold,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,879000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,879000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Cost of goods sold,Cost of goods sold,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostOfGoodsAndServicesSold_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:CostOfGoodsAndServicesSold,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,879000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,879000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Cost of goods sold,Cost of goods sold,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_0dIu13w--US87FMi9GnMcA,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_0dIu13w--US87FMi9GnMcA,-2108000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2108000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:ResearchSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_OtnPZyVOoE-wzMNKah-hlQ,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_ResearchSegmentMember_OtnPZyVOoE-wzMNKah-hlQ,-3800000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-3800000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:ResearchSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_mIb1twDAzkKIXwkIUyrCug,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_mIb1twDAzkKIXwkIUyrCug,-12085000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-12085000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CmcAndQualitySegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_cybYw_GuYkyC22ozjN3T0Q,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CmcAndQualitySegmentMember_cybYw_GuYkyC22ozjN3T0Q,-14200000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-14200000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CmcAndQualitySegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_P4VB7LVXW06wXUBpVqRG6Q,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember_P4VB7LVXW06wXUBpVqRG6Q,-1222000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1222000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:BiomarkersSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember__jAENRVAtUStQM5aZV08uA,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_BiomarkersSegmentMember__jAENRVAtUStQM5aZV08uA,-2500000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2500000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:BiomarkersSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_VEWQUdkHE0WBYoimkNF3Ng,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_VEWQUdkHE0WBYoimkNF3Ng,-10550000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-10550000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:DevelopmentAndComplianceSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_APCyxhKKDEm_D_Nm21ir_A,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_DevelopmentAndComplianceSegmentMember_APCyxhKKDEm_D_Nm21ir_A,-12600000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-12600000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:DevelopmentAndComplianceSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_ZQCEkQYAaUC1nKowqcY6cA,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_ZQCEkQYAaUC1nKowqcY6cA,-7339000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-7339000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:InfrastructureManagementAndFacilitiesSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_b2rNtU-IOUeloRBL82ZDHw,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_InfrastructureManagementAndFacilitiesSegmentMember_b2rNtU-IOUeloRBL82ZDHw,-7700000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-7700000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:InfrastructureManagementAndFacilitiesSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_J_HfgWyOyEmthGlY5uDzJA,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_J_HfgWyOyEmthGlY5uDzJA,-4398000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-4398000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CommercialPlanningSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_rfMx9mjt2kOcs3FWY0LQfQ,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_CommercialPlanningSegmentMember_rfMx9mjt2kOcs3FWY0LQfQ,-2600000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2600000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:CommercialPlanningSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_WyLf0D0LtEiEMG1uUZfpLA,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_WyLf0D0LtEiEMG1uUZfpLA,-12639000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-12639000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SupportFunctionsSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_ApTexnM2vEuGQZU1DWbYDA,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_SupportFunctionsSegmentMember_ApTexnM2vEuGQZU1DWbYDA,-9000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-9000000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SupportFunctionsSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_VF4ar1XaAUK2X1U5akxRvg,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_VF4ar1XaAUK2X1U5akxRvg,-1798000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1798000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:OtherSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_OO9VshVzJECW2aXI5l_8hw,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_us-gaap_StatementBusinessSegmentsAxis_adap_OtherSegmentMember_OO9VshVzJECW2aXI5l_8hw,-2539000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-2539000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:OtherSegmentMember,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-53018000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-53018000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:CostsAndExpenses,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-53018000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-53018000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-54939000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-54939000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:CostsAndExpenses,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-54939000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-54939000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:OperatingIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-45733000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-45733000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Loss from operations,Loss from operations,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:OperatingIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-45733000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-45733000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Loss from operations,Loss from operations,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:OperatingIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-49261000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-49261000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Loss from operations,Loss from operations,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:OperatingIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-49261000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-49261000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Loss from operations,Loss from operations,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InvestmentIncomeNonoperating_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:InvestmentIncomeNonoperating,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,910000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,910000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InvestmentIncomeNonoperating_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:InvestmentIncomeNonoperating,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,910000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,910000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InvestmentIncomeNonoperating_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:InvestmentIncomeNonoperating,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1345000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1345000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InvestmentIncomeNonoperating_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:InvestmentIncomeNonoperating,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,1345000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1345000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InterestExpenseNonoperating_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:InterestExpenseNonoperating,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-1881000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1881000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Interest expense,Interest expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InterestExpenseNonoperating_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:InterestExpenseNonoperating,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-1881000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-1881000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Interest expense,Interest expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-305000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-305000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-305000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-305000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-61000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-61000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-61000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-61000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,"Other income (expense), net","Other income (expense), net",IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-575000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-575000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-575000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-575000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-526000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-526000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-526000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-526000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_4,us-gaap:NetIncomeLoss,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,-47584000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-47584000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_4,us-gaap:NetIncomeLoss,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,-48503000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-48503000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Net loss attributable to ordinary shareholders,Net loss attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ResearchAndDevelopmentTaxAndExpenditureCredit_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:ResearchAndDevelopmentTaxAndExpenditureCredit,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1238000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1238000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Research and development tax and expenditure of credits,Research and development tax and expenditure of credits,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingOtherSegmentExpensesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ResearchAndDevelopmentTaxAndExpenditureCredit_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,adap:ResearchAndDevelopmentTaxAndExpenditureCredit,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,3499000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,3499000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Research and development tax and expenditure of credits,Research and development tax and expenditure of credits,Disclosures,http://www.adaptimmune.com/role/DisclosureSegmentReportingOtherSegmentExpensesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:Depreciation,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,2291000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2291000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:Depreciation,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,2291000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,2291000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:Depreciation,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,2771000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2771000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:Depreciation,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,2771000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,2771000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_0,us-gaap:AdjustmentForAmortization,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,175000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,175000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA_1,us-gaap:AdjustmentForAmortization,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,175000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,175000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_0,us-gaap:AdjustmentForAmortization,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,59000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,59000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw_1,us-gaap:AdjustmentForAmortization,Duration_1_1_2024_To_3_31_2024_JNUH7_-fb0O4iPI77ROVDw,59000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,59000.0,duration,2024-01-01,2024-03-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:InventoryDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 15 – Inventories</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"">On August 1, 2024, the Company received FDA approval for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, and commenced capitalization of inventory from this date.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"">Prior to August 1, 2024, regulatory approval and subsequent commercialization of TECELRA, and thus the possibility of future economic benefits from TECELRA sales, were not considered probable and inventory-related costs were expensed as incurred; as such, the inventory recognized on the balance sheet does not included any pre-launch inventory. At March 31, 2025, the gross value of pre-launch inventory held but not recognized was $5,819,000, which includes inventory that could be used for either clinical or commercial purposes.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The components of inventory are as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Raw materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,382</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,236</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Work-in-progress</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 133</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 84</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Finished goods</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 244</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total inventory, net</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 11,759</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,320</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Inventories,Inventories,Disclosures,http://www.adaptimmune.com/role/DisclosureInventories,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_InventoryGrossValueOfInventoryHeldButNotRecognized_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,adap:InventoryGrossValueOfInventoryHeldButNotRecognized,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5819000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,0,5819000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Gross value of pre-launch inventory held but not recognized,Gross value of pre-launch inventory held but not recognized,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfInventoryCurrentTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfInventoryCurrentTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2024</b></p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Raw materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,382</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,236</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Work-in-progress</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 133</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 84</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Finished goods</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 244</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total inventory, net</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 11,759</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 7,320</b></p></td></tr></table>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of components of inventory,Schedule of components of inventory,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesTable,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryRawMaterialsAndSupplies_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:InventoryRawMaterialsAndSupplies,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,11382000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11382000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Raw materials,Raw materials,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryRawMaterialsAndSupplies_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:InventoryRawMaterialsAndSupplies,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,7236000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7236000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Raw materials,Raw materials,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryWorkInProcess_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:InventoryWorkInProcess,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,133000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,133000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Work-in-progress,Work-in-progress,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryWorkInProcess_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,us-gaap:InventoryWorkInProcess,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,84000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,84000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Work-in-progress,Work-in-progress,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryFinishedGoods_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:InventoryFinishedGoods,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,244000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,244000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Finished goods,Finished goods,Disclosures,http://www.adaptimmune.com/role/DisclosureInventoriesDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryNet_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:InventoryNet,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,11759000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11759000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Inventory, net","Inventory, net",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryNet_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:InventoryNet,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,11759000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,11759000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Inventory, net","Inventory, net",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryNet_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_0,us-gaap:InventoryNet,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,7320000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7320000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Inventory, net","Inventory, net",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_InventoryNet_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_1,us-gaap:InventoryNet,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,7320000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,7320000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,"Inventory, net","Inventory, net",BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:CommitmentsAndContingenciesDisclosureTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 16 – Contingencies &amp; Provisions</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">MD Anderson Litigation</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On December 2, 2024, The University of Texas MD Anderson Cancer Center (“MD Anderson”) served litigation in the District Court of Harris County against Adaptimmune LLC relating to the strategic alliance entered into on September 26, 2016. MD Anderson claims damages of over $21 million (excluding legal fees and costs of court) caused by Adaptimmune’s breach of contract. Alternatively, MD Anderson brings an action for quantum meruit, promissory estoppel, unjust enrichment, negligent misrepresentation and reformation. The Company provided its Original Answer, Affirmative Defenses, Special Exceptions and Counterclaims on January 22, 2025 denying all allegations of the MD Anderson petition and counterclaiming for breach of contract. MD Anderson filed a motion to dismiss the Company’s counterclaim, Special Exceptions and Original Answer to the counterclaim denying all allegations in the counterclaim on February 11, 2025. <span style=""color:#231f20;"">This motion was dismissed in its entirety on March 26, 2025. The parties have agreed to mediation of the dispute and mediation is due during May 2025.</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The case has not yet proceeded to discovery stage and the Company does not believe there is any merit to the claims being brought by MD Anderson. As such, no provision for a loss contingency has been made as of March 31, 2025.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">2024-2025 Restructuring program</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Reduction in workforce</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On November 13, 2024 the Company announced a restructuring plan that aims to prioritize its commercial sarcoma franchise and certain research and development programs. As part of this restructuring, the Company is executing against a plan to achieve an approximately 33% reduction in workforce. The majority of the reduction in workforce was completed during the first quarter of 2025.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The redundancy process was initiated in the fourth quarter of 2024, with most employees leaving in the first quarter of 2025. Employees in certain roles will be retained during a transition period beyond the first quarter of 2025. Once the redundancy program is completed, it will result in a reduction of approximately 29% of global headcount. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The redundancy packages to be paid to departing staff comprise a combination of contractual termination benefits, relating to payments that arise from terms of employment contracts and statutory redundancy pay, and one-time employee termination benefits that were provided or enhanced specifically for this redundancy process. Due to the structure of the redundancy scheme and the different employment regulations affecting the Company’s U.K. and U.S. employees, some of the expense associated with the one-time employee termination benefits was recognized over the remaining period of employee service to be rendered. Contractual termination benefits and other one-time employee termination benefits were expensed and recognized in the year ended December 31, 2024. All expenses have been recognized in Selling, general and administrative expenses in the Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The amounts expected to be incurred in relation to the redundancy program were as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time employee termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total restructuring cost</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cumulative amount incurred to, December 31, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,102</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,809</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,911</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amount incurred in three months ended March 31,2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 263</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,399</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,662</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Remaining amount expected to be incurred in future periods</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 573</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 573</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total amount expected to be incurred</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,365</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,781</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 8,146</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below is a summary of the changes in the restructuring provision in the consolidated balance sheets in the three months ended March 31, 2025:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time employee termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total restructuring provision</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Liability at December 31, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,102</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,809</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,911</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_JBAlhExs4EK2gjlufS-bfA;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"">Costs incurred and charged to selling, general  and administrative expenses</span></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 271</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,267</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,538</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Adjustment to liability</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (8)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 132</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 124</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amounts utilised during the period</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,233)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,989)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,222)</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effects of foreign exchange rates</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 57</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 29</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 86</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Liability at March 31, 2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,189</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,248</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,437</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;font-weight:bold;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Contingencies & Provisions,Contingencies & Provisions,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisions,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_LossContingencyDamagesSoughtValue_Duration_12_2_2024_To_12_2_2024_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_sKVpywP4RkeZ0JP4Dd9L3w,us-gaap:LossContingencyDamagesSoughtValue,Duration_12_2_2024_To_12_2_2024_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_sKVpywP4RkeZ0JP4Dd9L3w,21000000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-6,21000000.0,duration,2024-12-02,2024-12-02,0001621227,http://www.sec.gov/CIK,duration_2024-12-02_2024-12-02,Damages claims on breach of contract,Damages claims on breach of contract,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_ReductionInWorkforcePercentage_Duration_11_13_2024_To_11_13_2024_rB-NR6_feUqf-PMCSAD27Q,adap:ReductionInWorkforcePercentage,Duration_11_13_2024_To_11_13_2024_rB-NR6_feUqf-PMCSAD27Q,0.33,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,2,0.33,duration,2024-11-13,2024-11-13,0001621227,http://www.sec.gov/CIK,duration_2024-11-13_2024-11-13,Reduction in workforce (as a percentage),Reduction in workforce (as a percentage),Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsReductionInWorkforceDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_RestructureHeadcountReductionPercentage_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:RestructureHeadcountReductionPercentage,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,0.29,Unit_Standard_pure_oCx_NdZSkkO9G7SuH_KyVw,2,0.29,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Percent of headcount reduction,Percent of headcount reduction,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsReductionInWorkforceDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time employee termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total restructuring cost</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cumulative amount incurred to, December 31, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,102</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,809</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,911</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amount incurred in three months ended March 31,2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 263</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,399</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,662</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Remaining amount expected to be incurred in future periods</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 573</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 573</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total amount expected to be incurred</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,365</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,781</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 8,146</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of amounts incurred in relation to the redundancy program,Schedule of amounts incurred in relation to the redundancy program,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,4102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4102000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Cumulative amount incurred to, December 31, 2024","Cumulative amount incurred to, December 31, 2024",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,1809000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1809000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Cumulative amount incurred to, December 31, 2024","Cumulative amount incurred to, December 31, 2024",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,5911000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5911000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,"Cumulative amount incurred to, December 31, 2024","Cumulative amount incurred to, December 31, 2024",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostIncurredCost_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,us-gaap:RestructuringAndRelatedCostIncurredCost,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,263000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,263000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Amount incurred in three months ended March 31,2025","Amount incurred in three months ended March 31,2025",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,None,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostIncurredCost_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,us-gaap:RestructuringAndRelatedCostIncurredCost,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,1399000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1399000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Amount incurred in three months ended March 31,2025","Amount incurred in three months ended March 31,2025",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostIncurredCost_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RestructuringAndRelatedCostIncurredCost,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,1662000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1662000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,"Amount incurred in three months ended March 31,2025","Amount incurred in three months ended March 31,2025",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,573000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,573000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Remaining amount expected to be incurred in future periods,Remaining amount expected to be incurred in future periods,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,573000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,573000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Remaining amount expected to be incurred in future periods,Remaining amount expected to be incurred in future periods,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,4365000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4365000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,3781000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3781000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,8146000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,8146000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRedundancyProgramDetails,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time employee termination benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total restructuring provision</b></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Liability at December 31, 2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,102</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,809</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,911</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_JBAlhExs4EK2gjlufS-bfA;""><span style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"">Costs incurred and charged to selling, general  and administrative expenses</span></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 271</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,267</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,538</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Adjustment to liability</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (8)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 132</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 124</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amounts utilised during the period</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (2,233)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,989)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (4,222)</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effects of foreign exchange rates</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 57</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 29</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 86</p></td></tr><tr><td style=""vertical-align:bottom;width:57.54%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Liability at March 31, 2025</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,189</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,248</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,437</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;font-weight:bold;visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Schedule of changes in the restructuring provision,Schedule of changes in the restructuring provision,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_d_Pwl92K906HdYYHG3PYCw,us-gaap:RestructuringReserve,As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_d_Pwl92K906HdYYHG3PYCw,4102000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4102000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_fX7g_94_FkmAX6qzKljOmQ,us-gaap:RestructuringReserve,As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_fX7g_94_FkmAX6qzKljOmQ,1809000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1809000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_0,us-gaap:RestructuringReserve,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,5911000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5911000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg_1,us-gaap:RestructuringReserve,As_Of_12_31_2024_DioDGGovFkeHoeptKm8byg,5911000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,5911000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2024-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2024-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_Rhj3f-NF0EGACWEUDGFNlA,us-gaap:RestructuringCharges,Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_Rhj3f-NF0EGACWEUDGFNlA,271000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,271000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,"Costs incurred and charged to selling, general and administrative expenses","Costs incurred and charged to selling, general and administrative expenses",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_eo2kZwAWUUqCP0o_kyWV0A,us-gaap:RestructuringCharges,Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_eo2kZwAWUUqCP0o_kyWV0A,1267000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1267000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,"Costs incurred and charged to selling, general and administrative expenses","Costs incurred and charged to selling, general and administrative expenses",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,us-gaap:RestructuringCharges,Duration_1_1_2024_To_12_31_2024_fQNHB-aweUuh8FJ7Cm5f9w,1538000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1538000.0,duration,2024-01-01,2024-12-31,0001621227,http://www.sec.gov/CIK,duration_2024-01-01_2024-12-31,"Costs incurred and charged to selling, general and administrative expenses","Costs incurred and charged to selling, general and administrative expenses",Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,-8000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,-8000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Adjustment to liability,Adjustment to liability,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,132000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,132000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Adjustment to liability,Adjustment to liability,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,124000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,124000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Adjustment to liability,Adjustment to liability,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,us-gaap:PaymentsForRestructuring,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,2233000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2233000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amounts utilised during the period,Amounts utilised during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,us-gaap:PaymentsForRestructuring,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,1989000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1989000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amounts utilised during the period,Amounts utilised during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:PaymentsForRestructuring,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,4222000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,4222000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Amounts utilised during the period,Amounts utilised during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_7eR4bh3WZkKGJJuoHrPgtQ,57000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,57000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Effects of foreign exchange rates,Effects of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2025_To_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_1abPYQtujESC7eVkntd6jg,29000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,29000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Effects of foreign exchange rates,Effects of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,86000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,86000.0,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Effects of foreign exchange rates,Effects of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesProvisionsRestructuringProvisionInConsolidatedBalanceSheetsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,us-gaap:RestructuringReserve,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_dV8pSYNcIEOY7l0r_xVpHA,2189000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,2189000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,us-gaap:ContractTerminationMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,us-gaap:RestructuringReserve,As_Of_3_31_2025_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_AK8K5Xh0HEiJ2sxJKSg1fQ,1248000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,1248000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,us-gaap:OneTimeTerminationBenefitsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_0,us-gaap:RestructuringReserve,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,3437000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3437000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A_1,us-gaap:RestructuringReserve,As_Of_3_31_2025_8AIVKIruPUqsWBdkioay_A,3437000,Unit_Standard_USD_Z2PvOo4Dr0qlawCYTzh7MA,-3,3437000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2025-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementCondensedConsolidatedBalanceSheets,None,None,None,2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
us-gaap_SubsequentEventsTextBlock_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,us-gaap:SubsequentEventsTextBlock,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 17 – Subsequent events</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">None. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p>",None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Subsequent events,Subsequent events,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEvents,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
ecd_NonRule10b51ArrAdoptedFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ecd:NonRule10b51ArrAdoptedFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
ecd_Rule10b51ArrAdoptedFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ecd:Rule10b51ArrAdoptedFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_NonRule10b51ArrModifiedFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:NonRule10b51ArrModifiedFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Non-Rule 10b5-1 Arrangement Modified,Non-Rule 10b5-1 Arrangement Modified,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
adap_Rule10b51ArrModifiedFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,adap:Rule10b51ArrModifiedFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,Rule 10b5-1 Arrangement Modified,Rule 10b5-1 Arrangement Modified,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
ecd_NonRule10b51ArrTrmntdFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ecd:NonRule10b51ArrTrmntdFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
ecd_Rule10b51ArrTrmntdFlag_Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,ecd:Rule10b51ArrTrmntdFlag,Duration_1_1_2025_To_3_31_2025_SMVgUtxdAEqq4TJmVLZ8eA,false,None,None,,duration,2025-01-01,2025-03-31,0001621227,http://www.sec.gov/CIK,duration_2025-01-01_2025-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2025-05-13,Q2,2025,Adaptimmune Therapeutics PLC
